SINGLE NUCLEOTIDE POLYMORPHISM ASSOCIATED WITH RISK OF INSULIN RESISTANCE DEVELOPMENT

Information

  • Patent Application
  • 20140057800
  • Publication Number
    20140057800
  • Date Filed
    December 13, 2011
    12 years ago
  • Date Published
    February 27, 2014
    10 years ago
Abstract
The present invention is directed to methods of identifying quantitative trait loci (QTL) markers associated with insulin resistance, and use of these markers to explain individual physiological responses to dietary glycemic load. In addition, expressional QTLs (eQTLs) have been identified to characterize the contribution of the genotype to variations in gene expression.
Description

The present invention pertains to different genetic markers of importance to the molecular mechanism involved in insulin resistance. A number of SNPs (single nucleotide polymorphisms) that are associated with insulin resistance have been located in the gene vesicle associated membrane protein-associated protein A (VAPA). Individual responses to a dietary challenge are expected to vary among individuals. Individuals with either a weak or strong response in insulin resistance upon dietary changes in glycemic load showed distinct genotype profiles. These markers have been extensively screened and connections between variation in SNPs and changes in insulin resistance in response to diets with different glycemic load have been identified.


An association between genetic variability in VAPA and insulin resistance has been found where several specific SNPs on identified quantitative trait loci (QTLs) are pinpointed.


Susceptibility loci traits for insulin resistance and SNPs which are involved in the molecular mechanism of the VAPA genetic interactions with insulin resistance have been identified. The protein encoded by this gene is a type IV membrane protein. It is present in the plasma membrane and intracellular vesicles. It may also be associated with the cytoskeleton. This protein may function in vesicle trafficking, membrane fusion, protein complex assembly and cell motility. Alternative splicing occurs at this locus and two transcript variants encoding distinct isoforms have been identified.


One aspect of the present invention is directed to specific SNPs as new markers of candidate QTLs related to genetic aspects of developing insulin resistance. Another aspect of the present invention involves the use of VAPA and plasma protein inhibitor of activated STAT-1 (PIAS1) as candidate genes for molecular mechanisms involved in insulin resistance. Yet another aspect of the present invention involves a specific marker SNP in the GIP (gastric inhibitory polypeptide) gene, a candidate expressional QTL (eQTL) affecting plasma plasminogen activator inhibitor-1 (PAI-1) concentrations related to insulin resistance.


The identified genetic markers can be used in the diagnosis of insulin resistance correlated with dietary diseases, especially glycemic loads. Furthermore such markers can be used in developing suitable drugs for regulating glycemic response in people with such diseases.


Furthermore, such markers associated with insulin resistance can be used to explain individual physiological responses to dietary glycemic load. SNP typing can be used to provide concrete dietary advice to persons genetically predisposed to type II diabetes (T2D).


BACKGROUND

Type 2 diabetes (T2D) is defined as chronic hyperglycemia, manifested when insulin production is overwhelmed by insulin resistance in target cells, leading to a decreased ability of glucose uptake (Tripathy and Chavez, Curr Diab Rep, 2010, 10(3): pp. 184-91, incorporated herein by reference). Insulin resistance, however, precedes the onset of T2D by many years (Pagel-Langenickel et al., Endocr Rev, 2010, 31(1): pp. 25-51, incorporated herein by reference), and in addition to be a risk factor for T2D it is also an independent predictor for e.g. hypertension, coronary heart disease (CHD), stroke, and cancer (Facchini et al., J Clin Endocrinol Metab, 2001, 86(8): pp. 3574-8, incorporated herein by reference). Even though obesity is associated with increased insulin resistance, individuals of normal weight do also experience variable sensitivity to insulin (McLaughlin et al., Metabolism, 2004, 53(4): pp. 495-9, incorporated herein by reference).


Already 30 years ago it was stated that the prevalence of T2D could be reduced by lifestyle changes, but so far the incidence of T2D has only been increasing, and the expansion is now called a modern epidemic (Meigs, Diabetes Care, 2010, 33(8): pp. 1865-71, incorporated herein by reference). There are at least two plausible explanations for this: Firstly, the dietary guidelines may be underestimating the influence of dietary glycemic load on hyperinsulinemia (Ludwig, Jama, 2002, 287(18): pp. 2414-23, incorporated herein by reference). Secondly, the same guidelines may be too general. The capability to study the complex genetics behind interindividual metabolic differences (Lairon et al., Public Health Nutr, 2009, 12(9A): pp. 1601-6, incorporated herein by reference) has been developed only recently, revealing benefits of personalized nutrition among high-risk persons (Kaput, J., Curr Opin Biotechnol, 2008, 19(2): pp. 110-20; Martinez et al., Asia Pac J Clin Nutr, 2008, 17 Suppl 1: p. 119-22; both incorporated herein by reference).


Insulin resistance is a pathophysiological trait characterised by an aberrant blood lipid profile, endothelial dysfunction, increased plasma concentration of procoagulant factors, and markers of inflammation (Goldberg, R. B., J Clin Endocrinol Metab, 2009, 94(9): pp. 3171-82, incorporated herein by reference). The etiology of insulin resistance is complex and unlikely to be the same in every individual. A major determinant, though, seems to be cytokine induced activation of proinflammatory pathways in insulin target cells, reducing insulin sensitivity. This activates and attracts immune cells, and establishes a feed forward loop resulting in macrophage infiltration of the tissue, and additional cytokine secretion (Olefsky and Glass, Annu Rev Physiol, 2010, 72: pp. 219-46, incorporated herein by reference). The inflammatory origin can be retraced to cellular stress, caused by metabolic imbalance, hence, called metaflammation (Hotamisligil, Nature, 2006, 444(7121): pp. 860-7, incorporated herein by reference). Prolonged malnutrition leads to chronic metaflammation, and may eventually cause degeneration of tissue, and onset of disease (Kushner et al., Arthritis Care Res (Hoboken), 2010, 62(4): pp. 442-6, incorporated herein by reference). Hyperglycaemia and hyperinsulinemia following a meal rich in easily digested carbohydrates are associated with cellular stress and increase of inflammatory markers (O'Keefe et al., J Am Coll Cardiol, 2008, 51(3): pp. 249-55, incorporated herein by reference). Diets with low glycemic load and glycemic index are suggested to silence metaflammation, and subsequently increase insulin sensitivity (Barclay et al., Am J Clin Nutr, 2008, 87(3): pp. 627-37; McKeown et al., Diabetes Care, 2004, 27(2): pp. 538-46; and Qi and Hu, Curr Opin Lipidol, 2007, 18(1): pp. 3-8; all incorporated herein by reference).


Current evidence suggests that insulin resistance and the associated abnormalities constitute complex phenotypes, explained by both environmental and genetic factors. The genetic makeup underlying these traits consists of several quantitative trait loci (QTL), whereof each QTL only explains a small fraction of the phenotype. The limited effects of these individual QTL make them difficult to identify, but the list of allelic variants associated with susceptibility to T2D development, in terms of single nucleotide polymorphisms (SNPs), is growing (Voight, B. F., et al., Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet, 2010. 42(7): p. 579-89, incorporated herein by reference). Also SNPs associated directly with insulin resistance have been found, but this line of research is in an early phase. (See Kantartzis et al., Clin Sci (Lond), 2009, 116(6): pp. 531-7; Liu et al., J Clin Endocrinol Metab, 2009, 94(9): pp. 3575-82; Palmer et al., Diabetes, 2004, 53(11): pp. 3013-9; Richardson et al., Diabetologia, 2006, 49(10): pp. 2317-28; Ruchat et al., Diabet Med, 2008, 25(4): pp. 400-6; and Smith et al., Diabetes, 2003, 52(7): pp. 1611-8; all incorporated herein by reference.)


The expression of a gene is the most basic phenotype in an organism. The genotype determines complex phenotypic traits through expression of several genes: expressional QTL (eQTL) (Jansen and Nap, Trends Genet, 2001, 17(7): pp. 388-91; and Schadt et al., Nature, 2003, 422(6929): pp. 297-302, both incorporated herein by reference). eQTL provide a direct link between genotype variation and gene- or pathway activities. The motivation to study how SNPs associated with a disease or a phenotypic trait may affect gene expression is to gain a direct understanding of the molecular mechanisms affected by the allelic variation (Rockman and Kruglyak, Nat Rev Genet, 2006, 7(11): pp. 862-72, incorporated herein by reference).


Homeostatic model assessment (HOMA) is a method for assessing surrogate measures of pancreatic β-cell function, insulin sensitivity, and insulin resistance derived from fasting blood glucose and insulin, alternatively insulin connecting peptide (C-peptide) concentrations (Wallace et al., Diabetes Care, 2004, 27(6): pp. 1487-95, incorporated herein by reference). The model was first proposed in 1985 (Matthews, et al., Diabetologia, 1985, 28(7): pp. 412-9, incorporated herein by reference), and an updated computer model (HOMA2) was published in 1998 (Levy et al., Diabetes Care, 1998, 21(12): pp. 2191-2, incorporated herein by reference). The calculation of insulin resistance designated as HOMA2 IR, is calibrated to a reference population, where the value 1 is set as normal (Wallace et al., 2004). HOMA2 IR was found to be a significant determinant of insulin resistance (Mojiminiyi et al., Clin Chem Lab Med, 2010, incorporated herein by reference).


In the present study, performed on modestly overweight but otherwise healthy individuals, associations between variation in SNPs and changes in insulin resistance in response to diets with different glycemic load were examined. SNPs were linked to genes and biological functions to develop an understanding of the molecular mechanisms potentially involved in onset of insulin resistance.







METHODS
Subjects and Study Outline

A randomized, controlled cross-over diet intervention trial was conducted on thirty-two young and healthy women and men, with body mass index (BMI, in kg/m2) between 24.5 and 27.5. Iso- and normocaloric meal replacement diets (MRDs) constituted all nutrients consumed during the study periods of two times six days with an eight day wash-out period in-between. Fasting blood samples were collected before and after each diet period, and effects of dietary intake on leukocyte gene expression profiles and insulin resistance were analyzed, as described previously ((Arbo I, Brattbakk H R, Langaas M et al. A balanced macronutrient diet induces changes in a host of pro-inflammatory biomarkers, rendering a more healthy phenotype; a randomized cross-over trial, 2010, (manuscript submitted), incorporated herein by reference). The two MRDs were: a high-carbohydrate diet (AHC) composed of 65:15:20 energy percent (E %) of carbohydrates, proteins, and fats; and a moderate-carbohydrate diet (BMC) with 27:30:43 E % of carbohydrates, proteins, and fats. The glycemic load of the AHC diet was calculated to be 2.71 times higher than the BMC diet.


Data extracted from samples were grouped and coded, according to diet and time of sampling. The abbreviations AHC0, AHC6, BMC0, and BMC6 denote before (day 0) and after (day 6) the AHC and the BMC diet intervention, respectively. Pair-wise analyses of data were performed for four different comparisons, which will be referred to throughout this paper: 1) AHC6-AHC0 and 2) BMC6-BMC0 identified responses to the AHC and the BMC diets, respectively, during six days on the respective diets. The comparison 3) BMC6-AHC6 identified the differences between the end-point responses to diet AHC and BMC after six days on diet, and finally, 4) (BMC6-BMC0)-(AHC6-AHC0) identified differences between the responses to AHC and BMC dieting. Complementary and more detailed information about subject recruitment, exclusion criteria, subject baseline characteristics, MRD compositions, and sampling techniques were described previously (Arbo I, Brattbakk H R, Langaas M et al. A balanced macronutrient diet induces changes in a host of pro-inflammatory biomarkers, rendering a more healthy phenotype; a randomized cross-over trial, 2010, (manuscript submitted), incorporated herein by reference).


Microarray Hybridization and Data Analysis

Microarray analysis and preprocessing of microarray data was performed as previously described (Arbo I, Brattbakk H R, Langaas M et al. A balanced macronutrient diet induces changes in a host of pro-inflammatory biomarkers, rendering a more healthy phenotype; a randomized cross-over trial, 2010, (manuscript submitted), incorporated herein by reference). Briefly, leukocyte gene expression profiling was done on the HumanHT-12 Expression BeadChip v3.0 (Illumina). After removal of two outlier samples, background correction based on negative controls, quantile-quantile normalization, signal log2-transformation, and removal of not detected or bad probes, 27 372 unique probes were left in the “gene expression dataset”. The paired analyses of AHC6-AHC0 and BMC6-BMC0 identified 3225 and 1370 differentially expressed genes, respectively, where 843 genes overlapped between the analyses. For the paired groups BMC6-AHC6 and (BMC6-BMC0)-(AHC6-AHC0), no differentially expressed genes were identified. Microarray data were submitted to ArrayExpress (www.ebi.ac.uk/arrayexpress, accession number: E-TABM-1073).


Analysis of the Bio-Plex Diabetes Panel and Assessment of Insulin Resistance

Protein concentration analyses and assessment of insulin resistance were performed as previously described (Arbo I, Brattbakk H R, Langaas M et al. A balanced macronutrient diet induces changes in a host of pro-inflammatory biomarkers, rendering a more healthy phenotype; a randomized cross-over trial, 2010, (manuscript submitted), incorporated herein by reference), using fasting EDTA-plasma samples. Bio-Plex Diabetes Panel assays (Bio-Rad Laboratories Inc., Hercules, Calif., USA) were performed using Luminex xMAP™ technology, with a Bio-Plex 200 suspension array reader, and the data was extracted with the Bio-Plex Manager 5.0 software (Bio-Rad Laboratories Inc.). Briefly, analysis of the paired groups showed decreased (P<0.05) plasma concentrations of visfatin (nicotinamide phosphoribosyltransferase, Nampt), and increased plasma concentration of resistin (P<0.05) during AHC dieting. Likewise, during BMC dieting the analysis showed decreased plasma concentrations of insulin, C-peptide, glucagon, plasminogen activator inhibitor-1 (PAI-1), glucagon-like peptide-1 (GLP-1), tumor necrosis factor-α (TNF), interleukin-6 (IL-6), and visfatin, and increased plasma concentrations of resistin. Gastric inhibitory polypeptide (GIP), ghrelin, and leptin did not respond to any of the diet interventions.


The HOMA2 calculator version 2.2.2® (Diabetes Trials Units, University of Oxford, www.dtu.ox.ac.uk/homacalculator/index.php) (Matthews et al., 1985) was used to determine changes in insulin resistance in terms of HOMA2 IR. There was an average decrease in HOMA2 IR during both the AHC diet and the BMC diet, but the downregulation was only significant during BMC dieting.


Genotyping

DNA was extracted from EDTA-blood using E.Z.N.A Blood DNA Kit (D3392, OMEGA Bio-Tek, Inc., Norcross, Ga., USA). The subjects were genotyped using the ˜200 K Cardio-MetaboChip (Metabochip) SNP array, an Infinium iSelect HD Custom Genotyping BeadChip (Illumina, San Diego, Calif., USA), designed by the Cardio-MetaboChip Consortium (Broad Institute, Cambridge, Mass., USA), and analyzed according to the Infinium HD Assay Ultra, Manual Experienced User Card. The Metabochip consists of SNPs associated with diseases or traits relevant to metabolic and atherosclerosis-cardiovascular endpoints, including T2D and hyperglycemia. The BeadChips were read by a BeadArray™ reader, and data were exported to GenomeStudio™ V2009, Genotyping V1.1.9 (Illumina), for visual quality control of genotype clustering, and extraction of quality measures (ChiTest100 and GenTrain Score) (Illumina, GenomeStudio™ Genotyping Module v1.0 User Guide. 2008, Illumina, Inc: San Diego, Calif., incorporated herein by reference). The ChiTest100 is a p-value calculated for each SNP, reflecting the deviation of that SNP to the genotype distribution according to the Hardy-Weinberg Equilibrium (HWE), using the χ2 statistic, normalized to 100 subjects. GenTrain Score is a measure of SNP clustering performance indicated by a number increasing with cluster quality, form 0 to 1.


Candidate Gene Selection

A set of 22 transcription regulators and seven ligand-dependent nuclear receptors central to insulin resistance development (Olefsky and Glass, 2010; Hotamisligil, 2006; and Wymann and Schneiter, Nat Rev Mol Cell Biol, 2008, 9(2): pp. 162-76; all incorporated herein by reference) were selected. The selected candidate genes were uploaded to the Ingenuity Pathway Analysis 8.7 (IPA Ingenuity Systems®, Redwood City, Calif., USA, www.ingenuity.com) to find the upstream activators and inhibitors, and downstream target genes of the transcription regulators and the nuclear receptors. No filters were applied in IPA regarding species, tissues or cell lines, but an upper limit of 150 upstream and 150 downstream genes was defined. The SNPs linked to the extended selected list of 276 candidate genes were extracted from the dbSNP database (www.ncbi.nlm.nih.gov/projects/SNP, National Center for Biotechnology Information, U.S. National Library of Medicine, Bethesda), and matched with 469 SNPs on the Metabochip. These 469 SNPs (linked with 276 candidate genes) were uploaded to the web server FASTSNP (Yuan et al., Nucleic Acids Res, 2006, 34 (Web Server issue): pp. W635-41, incorporated herein by reference) to prioritize the SNPs that were most likely to have functional effect on the expression of the linked gene. According to a decision tree, each SNP was assigned a risk score between 0 and 5. Risk score 0 means that the SNP has no known effect (e.g. located in a downstream or upstream untranslated region, nearby the gene), and 5 means that the SNP has a functional effect (e.g. introduces a stop codon and hence premature translational termination). Basically all SNPs with risk score lower than 2 were discarded. Since several SNPs with risk score 2 or higher were linked to a single gene, we defined an upper limit of seven SNPs per gene. That was done by increasing the risk score claim one factor at the time, until the number of SNPs was at most seven. The result was a list of 190 SNPs.


SNP Selection

Four different selections of SNPs were used in the analyses:

    • 1. The ref-SNP selection—71 061 Metabochip SNPs assigned with a reference SNP ID (rs) with more than one SNP type among the 32 subjects. The ref-SNP selection was used to screen for SNPs that could be associated with HOMA2 IR.
    • 2. The gene-SNP selection—a subset of 23 382 SNPs linked according to the dbSNP database with one or more genes present in the “gene expression dataset”. This resulted in 35 082 SNP and gene expression value (log2-ratio) pairs, since several genes were represented with multiple probes on the HumanHT-12 Expression BeadChip. The gene-SNP selection was used to screen for pairs where the SNP was associated with the expression of the gene.
    • 3. The candidate gene-SNP selection—the subset of 190 SNPs that according to the dbSNP database were linked with the genes in the candidate gene list (described above). This resulted in 364 SNP and gene expression value pairs. The candidate gene-SNP selection was used to screen for association between SNPs and HOMA2 IR, and associations between SNPs and gene expression.
    • 4. The diabetes panel-SNP selection—a subset of 7 SNPs that according the dbSNP database were linked with genes coding for the proteins on the diabetes panel. This set of SNP selection was examined for association with the expression of proteins or genes of the diabetes panel. The SNPs were also tested for association with HOMA2 IR.


Statistical Analyses

For all analyses a two-stage strategy was performed. In the first stage, analysis of variance (ANOVA) was performed to test the null hypothesis, whether there was no difference in either HOMA2 IR, gene expression (log2-ratio), or protein concentration (loge-ratio) change between the genotypes. Genotype was used as covariate, and changes as response variables. P-values were adjusted for multiple testing using the Benjamini-Hochberg step up algorithm (Benjamini and Hochberg, Journal of the Royal Statistical Society. Series B (Methodological), 1995, 57(1): pp. 289-300, incorporated herein by reference) to control the false discovery rate (FDR). In the second stage, a one-sample, two-sided t-test was assigned to test if the change in HOMA2 IR, gene expression, or protein concentration, was different from zero for any of the genotypes. For the ref-SNP selection and the gene-SNP selection, the second stage was performed only for the 100 best ranked entries, according to the ANOVA p-values. Hence, eight Top100 lists were generated, one for each comparison, the ref-SNP selection and the gene-SNP selection separately (see Supplementary tables 1-8). Within these lists the t-test p-values were adjusted for multiple testing using the Benjamini-Hochberg step up algorithm.


Unsupervised hierarchical clustering analyses were performed, using Manhattan distance measures and complete linkage. PCA was performed with discrete data, where the three possible genotypes were represented by numerical values (0, 1, 2). Analyses were performed using the R statistical analysis framework (R Development Core Team, R: A Language and Environment for Statistical Computing, 2010; Available from: www.r-project.org, incorporated herein by reference).


Functional analysis to identify biological functions and diseases significantly associated with gene lists were performed using IPA 8.7 (Ingenuity). Since the Metabochip is custom made, biased by SNPs associated with metabolic and cardiovascular traits, a custom reference set was also used in all analyses. This was composed of all the 10 515 genes that according to the dbSNP database were linked to the 71 061 SNPs on the Metabochip. P-values were adjusted for multiple testing using the Benjamini-Hochberg step up algorithm.


RESULTS

SNPs Associated with HOMA2 IR


Insulin resistance is a complex trait and the contribution of each single locus to the phenotype is small. To propose loci involved in the manifestation of this trait, the environmental homeostasis was challenged by introducing the subjects to two different diets. The responding change in HOMA2 IR for the four comparisons was related to SNPs in the ref-SNP selection. The biological relevance to insulin resistance was examined for all SNPs with FDR<0.2, a cut-off used in larger cohorts (>3000 subjects) earlier (Povel et al., Int J Obes (Lond), 2010, 34(5): pp. 840-5, incorporated herein by reference).


The change in HOMA2 IR during the AHC diet was associated (FDR<0.1) with four SNPs, with identical allele distribution between the subjects (FIG. 1A). The first SNP, rs16961756 (cgggccttcctcgccagcacctccattcct[a/g]aggctcacgtgggagagacagtgtggagag) (SEQ ID NO: 1) (Chr17:17359619, G→A) was located 126 base pairs (bp) upstream of a putative pseudogene (LOC100288179). This finding is supported by similar allele distribution in the closest neighboring SNP on the Metabochip, rs1242483 GAAGTTAAGAGTAAATAAAATAGTCA[C/T]GTTTGGGAGCATGAAGGAGCCGGC A (Chr17:17351675, T→C, P=0.002) (SEQ ID NO: 2)


The three other SNPs,


rs29095 (tccctcgaataaaggtgaaatttttaaaat[a/c]tcagtgaataggaatgtgcaaagactaag) (SEQ ID NO: 3) (Chr18:9957549),


rs7237794 (ctgcccctcccgacacagcacatacacaca[c/t]tgacgttttgctactacagcatatagcctt) (SEQ ID NO: 4) (Chr18:9951304), and


rs917688 (ttctctcatgcttaatatttggaactataa[a/c]gctaaaggccattgacgtagctaaaaatct) (SEQ ID NO: 5)(Chr18:9962736), (Chr18:9951304 . . . 9962736, C→A, T→C, and C→A, respectively) were closely linked, and rs7237794 and rs917688 were located in an intron region, and in the untranslated region of the 3′end of the gene vesicle-associated membrane protein-associated protein A, 33 kDa (VAPA), respectively. The 29 subjects homozygous for the consensus allele had an average downregulation of HOMA2 IR during the AHC diet (estimate of average change ( x)=−0.279, FDR=0.004), while the three remaining heterozygotes had an average upregulation ( x=1.000, FDR=0.098). This response to the AHC diet was only modestly reflected on the VAPA gene expression level. There was no change in HOMA2 IR among the homozygotes ( x=0.008, P=0.859), while among the heterozygotes there was a decrease ( x=−0.216, P=0.014).


Another association (FDR<0.02) was found between HOMA2 IR change during the AHC diet and the SNP rs10803976 (FIG. 1B) (Chr2:185428946, C→T)(CATTAA AAGCTATCATCTAACATTGC[C/T]TGGAGTGTTTATTTTTAAGTGCATA) (SEQ ID NO: 6), located 34 Kbp upstream of the nearest gene (zinc finger protein 804A). The 27 individuals homozygous for the consensus allele experienced an average decrease in HOMA2 IR during the AHC diet ( x=−0.311, FDR=0.004). The four heterozygotes experienced an average increase during the AHC diet ( x=0.800, FDR=0.103), and the response difference between the AHC ( x=0.800) diet and the BMC diet ( x=−0.275) was significant ( x=−1.075, FDR=0.048). Only one was homozygous for the alternative allele.


The same procedure was followed for the candidate gene-SNP list. HOMA2 IR change during the BMC diet was associated with the SNP rs6494711 (FIG. 1C) (aaaattgaggaaaatcccagaagatagagc[c/t]aaaagacaagagatgtaaaaatgcacaagg) (SEQ ID NO: 7) (FDR=0.047, Chr15:68374027, T→C). Those homozygous for this SNP had an average decrease in HOMA2 IR (TT, n=9, x=−0.644, P=0.004; CC, n=9, x=−0.422, P=0.003), while the heterozygotes had no significant change (CT, n=14, x=0.021, P=0.773). The SNP rs6494711 was located in an intron region of the transcription factor protein inhibitor of activated STAT-1 (PIAS1). The nearest neighbouring SNP on the Metabochip, rs1489595 AATTTTCTGTTTACACAAGTGATTCT[A/G]TAAGCAAACCAGGGTTCTCCATGGT (SEQ ID NO: 8) (Chr15:68377126, A→G, P=0.014), also located in an intron region of PIAS1, showed the same changes in HOMA2 IR among hetero- and homozygotes. The genotype specific changes were not reflected in the mRNA expression data of PIAS1.


SNP in the GIP Gene is Associated with PAI-1 Protein Concentration in Plasma


To screen for cis- and trans-regulating eQTLs that affected expression of genes central in pathogenesis of T2D, we tested the association between the SNPs in the diabetes panel-SNP and HOMA2 IR. Association was detected for the SNP rs2291726 (FIG. 1D) (Chr17:47039254, C→T)(TCTAGGGACACTTGAATCTTTTAATA[C/T]C TGAACCCCAAAAGCAGAGGGTACC) (SEQ ID NO: 9) and the protein concentration of PAI-1 in plasma. The SNP was located in an intron region of the gene coding for GIP. For the eight individuals homozygous for the consensus allele, the average protein concentration (loge-ratio) changed during the AHC diet differed significantly from the BMC diet ( x=−1.003, P=0.016). For the 21 heterozygotes and the three homozygous for the alternative allele there were only minor or no differences in PAI-1 concentration changes ( x=−0.037, P=0.695; x=−0.075, P=0.848, respectively). This suggests that nucleotide variation in GIP mRNA may have downstream effects on protein concentration of PAI-1. However, precaution has to be made interpreting this finding, since the deviation from HWE is significant (P=0.029).


SNPs Associated with HOMA2 IR Change are Related to Type 2 Diabetes


Since insulin resistance is manifested by numerous QTL, we wanted to explore how the genotype profile in each individual correlated with the change in HOMA2 IR in response to the diets. Heatmaps were generated showing hierarchical clustering of the ref-SNP selection Top100 SNPs associated with HOMA2 IR. SNPs were clustered according to allele distribution, and the subjects were sorted according to HOMA2 IR differences (increasing from left to right, FIG. 2A) in the comparison corresponding to the Top100 list. The genotype profiles for the subjects with the largest increase in HOMA2 IR during the AHC diet were notable (FIG. 2A, right). Some clusters of SNPs seem to have a dominant role influencing HOMA2 IR. The genotype profiles of the subjects with the largest decrease in HOMA2 IR during the BMC diet also differed distinctively from the rest of the subjects (FIG. 2B, left).


Since the subjects with the strongest increase in HOMA2 IR during the AHC diet had such a distinct genotype profile, these were suspected to be involved in our most significant associations between SNP and HOMA2 IR. To determine if this was due to technical artifacts we generated a dendrogram and a PCA plot (showing the three first principal components) based on allele information from the 71 061 SNPs to examine whether we had outlier individuals (FIG. 3). The figures suggest that there were two outliers, subjects 22 and 25, but neither of these contributed to the most significant associations between genotype and HOMA2 IR. However, those who did (especially subject 2, 12, 15, and 28) could not be considered as being outliers in these analysis, clustering well with the other subjects.


To explore functional and biological information about the SNPs that showed the highest association with HOMA2 IR, we assessed IPA's Functional Analysis. We extracted the genes that according the dbSNP database were linked to all the SNPs in the ref-SNP selection Top100 lists. We found 366 unique SNPs in the four lists, and these were linked with 150 unique genes. The gene set was significantly associated with T2D, displaying an FDR-value equal to 6.39×10−13 for the sum of all four Top100 lists (Table 1). The SNPs included in the ref-SNP selection Top100 lists were also associated with several traits that usually co-exist with insulin resistance, like cardiovascular disorder, hypertension, and immunological disorder.


Genotype Specific Gene Expression Changes

To identify potential insulin resistance eQTLs, we matched the genes of the Top100 pairs from the gene-SNP lists for the four comparisons, with the genes related to insulin resistance in the literature, using the following search in PubMed (NCBI, NIH, USA): (“Diabetes Mellitus, Type 2”[MeSH] OR “Insulin resistance”[MeSH] OR “Hyperglycemia”[MeSH] OR “Insulin-Secreting Cells”[MeSH]). None of the pairs of SNPs and genes related to insulin resistance showed significant association between genotype and expression changes, but several genes showed significant genotype specific expression changes (FDR<0.05) in response to diet AHC and BMC (Table 2). This suggests that genotype is a considerable variable, contributing to interindividual gene expression variability.


DISCUSSION

In this study we have defined a method to relate SNPs to phenotypic changes in response to an intervention, and applied this method to identify potential susceptibility loci for insulin resistance. The method should also be applicable on larger cohorts. We observed distinctive genotype profiles among strong responders to high and low glycemic load, concerning increase and decrease of insulin resistance, respectively. Several eQTL were found linked to genes related to insulin resistance, showing inter-genotype variability. On a limited number of subjects, we successfully applied statistical and bioinformatical methods new to this area of genetic research.


Our most significant finding is association of insulin resistance to VAPA, a protein previously shown to play a role in the vesicle budding and fusion events involving protein transport in cells (Weir et al., Biochem Biophys Res Commun, 2001, 286(3): pp. 616-21, incorporated herein by reference). GLUT4 is translocated to the surface of myocytes and adipocytes in response to insulin binding to its receptor. Various proteins control this GLUT4 translocation, including VAMP2 and syntaxin-4. VAPA interacts with both of these proteins in skeletal myoblasts, and is suggested to be a regulator of VAMP2 availability in insulin-dependent GLUT4 translocation (Foster, et al., Traffic, 2000, 1(6): pp. 512-21, incorporated herein by reference). The effect of insulin on GLUT4 translocation in monocytes is discussed, but there are indications that systemic insulin resistance is indicated by the presence of GLUT4 receptors on the monocyte surface (Mavros et al., Diabetes Res Clin Pract, 2009, 84(2): pp. 123-31, incorporated herein by reference. There is a strong association between variation in the SNPs rs29095, rs7237794, and rs917688 (FIG. 1A) and insulin resistance, modestly reflected in gene expression, showing that the subjects with decreased leukocyte expression of VAPA during the AHC diet experience an increased insulin resistance. This suggests that the chromosome region where these SNPs are located is a susceptibility locus concerning insulin resistance. It remains to be seen if leukocytes have a role as insulin target cells. The genetic variability in VAPA, eventually contributing to a change in insulin resistance, may be caused by stronger gene expression changes in cells traditionally regarded as insulin target cells. As far as we know, this is the first time an association is found between genetic variability in VAPA and insulin resistance. Earlier the SNP rs29066, located in the 3′UTR region of VAPA, between rs917688 and rs29095 has been found associated with bipolar disorder (Lohoff et al., J Neural Transm, 2008, 115(9): pp. 1339-45, incorporated herein by reference).


There are not many known genes regulated by the transcription factor PIAS1, but three of them, myogenin (MYOG) (Hsu et al., J Biol Chem, 2006, 281(44): pp. 33008-18, incorporated herein by reference), actin, alpha 2, smooth muscle, aorta (ACTA2, member of F-actin) (Kawai-Kowase et al., Mol Cell Biol, 2005, 25(18): pp. 8009-23, incorporated herein by reference), and cyclin-dependent kinase inhibitor 1A (CDKN1A) (Megidish et al., J Biol Chem, 2002, 277(10): pp. 8255-9, incorporated herein by reference) are all mediators of insulin induced signalling, shown in a variety of cells, including neutrophils, adipocytes, myocytes, pancreatic islet cells, and intestinal endocrine cells. (See Chodniewicz and Zhelev, Blood, 2003, 102(6): pp. 2251-8; Inoue et al., J Biol Chem, 2008, 283(30): pp. 21220-9; Kaneto et al., Diabetologia, 1999, 42(9): pp. 1093-7; Lim et al., Endocrinology, 2009, 150(12): pp. 5249-61; Sumitani et al., Endocrinology, 2002, 143(3): pp. 820-8; and Yoshizaki et al., Mol Cell Biol, 2007, 27(14): pp. 5172-83; all incorporated herein by reference.)


The association we found between the SNP rs6494711 and insulin resistance showed that homozygotes for both the consensus and the alternative allele had a decrease in insulin resistance during the BMC diet, but the heterozygotes had no significant change. However, the genotype specific change was not reflected in the mRNA expression data of PIAS1, but the effect of the transcription factors could be controlled by post-transcriptional activation. The effect may also be mediated through gene expression responses in other cells more insulin sensitive than leukocytes.


Increased PAI-1 concentration in the liver is associated with insulin resistance in mice (Takeshita et al., Metabolism, 2006, 55(11): pp. 1464-72, incorporated herein by reference), and loss of affinity between GIP and GIP-receptor affect localization of PAI-1 to mouse plasma (Hansotia et al., J Clin Invest, 2007, 117(1): pp. 143-52, incorporated herein by reference). Since GIP-secretion is stimulated by glucose, this could explain why genetic variation in the GIP gene was associated with changes in PAI-1 protein concentrations in plasma.


Today the recommendation of daily intake of carbohydrates in Norway is 50-60 E % (Utviklingen i norsk kosthold, Vol. 2008, Utviklingen i norsk kosthold 2008, Oslo: Direktoratet, 2008, 27 s, incorporated herein by reference). Such a high fraction will contribute to a high dietary glycemic load, unless considerable caution is taken to choose carbohydrate sources with low glycemic index. With precaution, regarding the small sample size, our results suggest that some individuals are sensitive to high glycemic load, which is shown by an increase in insulin resistance during high-carbohydrate dieting (AHC) (FIG. 2A). The same individuals have a distinct genotype profile for the SNPs most highly associated with changes in insulin resistance. Likewise, there are subjects that benefit more than others from low dietary glycemic load (FIG. 2B), also with a distinct genotype profile. The observation that a significant number of these SNPs are located in genes already associated with T2D and other traits related to insulin resistance strengthens our hypothesis that one could discern strong and weak responders to glycemic load, by their genotype profile. However, our contribution to identify these QTLs affecting insulin resistance should be corroborated in larger studies. Reliable personalized nutritional advice is something still far ahead, and the theme may also raise considerable ethical debate, but our results suggest that the population at large, but especially subjects predisposed to develop T2D, should be aware of the glycemic challenge that a diet with high glycemic load gives.


The use of genotyping data to link gene expression differences with phenotypes has increased markedly the last years. However, the use of genetic variation to stratify responses to a homeostatic challenge, like a diet intervention, has not been quite as common. The reason might be that the sample size required to gain significant results far exceeds what is easily manageable in an intervention study. We have shown that genotype is a source of interindividual variability in the response to a change in glycemic load, and suggest that genotype information can be integrated as an explanatory variable in microarray gene expression analysis.


Some obvious limitations need to be acknowledged in our study. What is already mentioned is the limited sample size. Whereas the study of average responses to a dietary intervention in a controlled cross-over study has produced robust findings (Arbo I, Brattbakk H R, Langaas M et al., A balanced macronutrient diet induces changes in a host of pro-inflammatory biomarkers, rendering a more healthy phenotype; a randomized cross-over trial, 2010, (manuscript submitted), incorporated herein by reference), dividing the subjects into two or three groups based on genotype inevitably decreases the statistical power. We nevertheless used reasonable criteria to declare associations of SNPs and eQTL (FDR<0.05), while acknowledging that of course in largest studies much more significant association confidence can be obtained. We considered various quality criteria of the SNPs that could account for aberrant behaviour in our statistical tests. One quality criterion concerns the Hardy-Weinberg equilibrium (HWE). In a population, deviation from HWE may be indicative of selective pressure, but because most genes are not under selection it can also be used as an indicator of problems in the genotyping procedure leading to bias in the observed allele frequencies (Greene et al., Lect Notes Comput Sci, 2010, 6023(LNCS): pp. 74-85, incorporated herein by reference). Another reason why the allele distribution might deviate from HWE is the relatively small sample size of the current study, making it vulnerable to biased selection of subjects. Nevertheless, except where noted, none of the SNPs for which we found associations showed a gross skewness in allele frequencies that would significantly violate HWE, and indeed all passed the SNP call quality criteria of the Genotyping V1.1.9 software (Illumina). To ascertain the genotyping and HWE quality of each individual SNP is challenging, so we did carefully consider these quality criteria when interpreting the results of individual SNPs.


Hierarchical clustering and PCA revealed two genetical outliers in our sample size (FIG. 3). Why these subjects deviate from the others is not known, but to re-analyse the data without these outliers would be a reasonable approach.


Leukocytes are an easy accessible source for transcriptome profiling, and an obvious choice to screen for inflammatory gene expression changes in response to food. However, the knowledge on insulin responsiveness is limited. The inflammatory properties of monocytes and macrophages are central in the development of insulin resistance in insulin target cells, like adipocytes and myocytes. But it is not known whether the established molecular mechanisms behind insulin resistance are the same in leukocytes. We have shown earlier that monocytes are insulin responsive in a dose dependent manner (Ingerid Arbo, Cathinka L Halle, Darshan Malik, et al. Insulin induces fatty acid desaturase expression in human monocytes, 2010, (manuscript submitted), incorporated herein by reference), inducing increased desaturase transcription. However, this does not guarantee that we can expect significant association between leukocyte gene expression and changes in insulin resistance, considering an earlier finding that gene expression profiles in leukocytes and adipocytes deviate (Brattbakk H R, Arbo I, Aagaard S, et al. Balanced caloric macronutrient composition downregulates immunological gene expression in human blood cells—adipose tissue diverges, 2010, (manuscript submitted), incorporated herein by reference). This demonstrates the need to investigate not only blood, but also additional parallel sampled biopsies of well established insulin target tissue, like adipose tissue.


Of the SNPs disclosed herein, it is seen that some are directly related to the genes for VAPA, Pias1 and GIP, while some are closely related thereto and can serve as “surrogate” markers. These SNPs are more specifically: rs16961756, rs1242483, rs29095, rs7237794, rs917688, rs6494711, rs1489595 and rs2291726.


The SNPs may serve as new markers of candidate QTL contributing to explain the genetic aspect of insulin resistance development. Also, VAPA and PIAS1 are new candidate genes involved in the molecular mechanisms behind insulin resistance. Finally, certain SNPs are candidate eQTL for plasma PAI-1 concentration, also related to insulin resistance. Our results have demonstrated the added value of incorporating genotype data in gene expression analysis to explain interindividual variability. A genotype profile of specific SNPs can distinguish weak and strong responders to glycemic load, with respect to insulin resistance. SNP typing may eventually be used to provide concrete dietary advice to persons genetically predisposed to T2D.


REFERENCES



  • 1. Tripathy, D. and A. O. Chavez, Defects in insulin secretion and action in the pathogenesis of type 2 diabetes mellitus. Curr Diab Rep, 2010. 10(3): p. 184-91.

  • 2. Pagel-Langenickel, I., et al., The role of mitochondria in the pathophysiology of skeletal muscle insulin resistance. Endocr Rev, 2010. 31(1): p. 25-51.

  • 3. Facchini, F. S., et al., Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab, 2001. 86(8): p. 3574-8.

  • 4. McLaughlin, T., et al., Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism, 2004. 53(4): p. 495-9.

  • 5. Meigs, J. B., Epidemiology of type 2 diabetes and cardiovascular disease: translation from population to prevention: the Kelly West award lecture 2009. Diabetes Care, 2010. 33(8): p. 1865-71.

  • 6. Ludwig, D. S., The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. Jama, 2002. 287(18): p. 2414-23.

  • 7. Lairon, D., et al., Nutrigenetics: links between genetic background and response to Mediterranean-type diets. Public Health Nutr, 2009. 12(9A): p. 1601-6.

  • 8. Kaput, J., Nutrigenomics research for personalized nutrition and medicine. Curr Opin Biotechnol, 2008. 19(2): p. 110-20.

  • 9. Martinez, J. A., et al., Genotype-dependent response to energy-restricted diets in obese subjects: towards personalized nutrition. Asia Pac J Clin Nutr, 2008. 17 Suppl 1: p. 119-22.

  • 10. Goldberg, R. B., Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab, 2009. 94(9): p. 3171-82.

  • 11. Olefsky, J. M. and C. K. Glass, Macrophages, inflammation, and insulin resistance. Annu Rev Physiol, 2010. 72: p. 219-46.

  • 12. Hotamisligil, G. S., Inflammation and metabolic disorders. Nature, 2006. 444(7121): p. 860-7.

  • 13. Kushner, I., D. Samols, and M. Magrey, A unifying biologic explanation for “high-sensitivity” C-reactive protein and “low-grade” inflammation. Arthritis Care Res (Hoboken), 2010. 62(4): p. 442-6.

  • 14. O'Keefe, J. H., N. M. Gheewala, and J. O. O'Keefe, Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol, 2008. 51(3): p. 249-55.

  • 15. Barclay, A. W., et al., Glycemic index, glycemic load, and chronic disease risk—a meta-analysis of observational studies. Am J Clin Nutr, 2008. 87(3): p. 627-37.

  • 16. McKeown, N. M., et al., Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care, 2004. 27(2): p. 538-46.

  • 17. Qi, L. and F. B. Hu, Dietary glycemic load, whole grains, and systemic inflammation in diabetes: the epidemiological evidence. Curr Opin Lipidol, 2007. 18(1): p. 3-8.

  • 18. Voight, B. F., et al., Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet, 2010. 42(7): p. 579-89.

  • 19. Kantartzis, K., et al., The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans. Clin Sci (Lond), 2009. 116(6): p. 531-7.

  • 20. Liu, P. H., et al., Genetic variants of TCF7L2 are associated with insulin resistance and related metabolic phenotypes in Taiwanese adolescents and Caucasian young adults. J Clin Endocrinol Metab, 2009. 94(9): p. 3575-82.

  • 21. Palmer, N. D., et al., Association of protein tyrosine phosphatase 1B gene polymorphisms with measures of glucose homeostasis in Hispanic Americans: the insulin resistance atherosclerosis study (IRAS) family study. Diabetes, 2004. 53(11): p. 3013-9.

  • 22. Richardson, D. K., et al., Association between variants in the genes for adiponectin and its receptors with insulin resistance syndrome (IRS)-related phenotypes in Mexican Americans. Diabetologia, 2006. 49(10): p. 2317-28.

  • 23. Ruchat, S. M., et al., Associations between glucose tolerance, insulin sensitivity and insulin secretion phenotypes and polymorphisms in adiponectin and adiponectin receptor genes in the Quebec Family Study. Diabet Med, 2008. 25(4): p. 400-6.

  • 24. Smith, S. R., et al., A promoter genotype and oxidative stress potentially link resistin to human insulin resistance. Diabetes, 2003. 52(7): p. 1611-8.

  • 25. Jansen, R. C. and J. P. Nap, Genetical genomics: the added value from segregation. Trends Genet, 2001. 17(7): p. 388-91.

  • 26. Schadt, E. E., et al., Genetics of gene expression surveyed in maize, mouse and man. Nature, 2003. 422(6929): p. 297-302.

  • 27. Rodman, M. V. and L. Kruglyak, Genetics of global gene expression. Nat Rev Genet, 2006. 7(11): p. 862-72.

  • 28. Wallace, T. M., J. C. Levy, and D. R. Matthews, Use and abuse of HOMA modeling. Diabetes Care, 2004. 27(6): p. 1487-95.

  • 29. Matthews, D. R., et al., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985. 28(7): p. 412-9.

  • 30. Levy, J. C., D. R. Matthews, and M. P. Hermans, Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care, 1998. 21(12): p. 2191-2.

  • 31. Mojiminiyi, O. A. and N. A. Abdella, Effect of homeostasis model assessment computational method on the definition and associations of insulin resistance. Clin Chem Lab Med, 2010.

  • 32. Illumina, GenomeStudio™ Genotyping Module v1.0 User Guide. 2008, Illumina, Inc: San Diego, Calif.

  • 33. Wymann, M. P. and R. Schneiter, Lipid signalling in disease. Nat Rev Mol Cell Biol, 2008. 9(2): p. 162-76.

  • 34. Yuan, H. Y., et al., FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res, 2006. 34(Web Server issue): p. W635-41.

  • 35. Benjamini, Y. and Y. Hochberg, Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B (Methodological), 1995. 57(1): p. 289-300.

  • 36. R Development Core Team, R: A Language and Environment for Statistical Computing. 2010; Available from: www.R-project.org.

  • 37. Povel, C. M., et al., Glucose levels and genetic variants across transcriptional pathways: interaction effects with BMI. Int J Obes (Lond), 2010. 34(5): p. 840-5.

  • 38. Weir, M. L., et al., VAP-A binds promiscuously to both v- and tSNAREs. Biochem Biophys Res Commun, 2001. 286(3): p. 616-21.

  • 39. Foster, L. J., et al., A functional role for VAP-33 in insulin-stimulated GLUT4 traffic. Traffic, 2000. 1(6): p. 512-21.

  • 40. Mavros, Y., D. Simar, and M. A. Singh, Glucose Tranporter-4 expression in monocytes: a systematic review. Diabetes Res Clin Pract, 2009. 84(2): p. 123-31.

  • 41. Lohoff, F. W., et al., Association between polymorphisms in the vesicle-associated membrane protein-associated protein A (VAPA) gene on chromosome 18p and bipolar disorder. J Neural Transm, 2008. 115(9): p. 1339-45.

  • 42. Hsu, Y. H., et al., Sumoylated SnoN represses transcription in a promoter-specific manner. J Biol Chem, 2006. 281(44): p. 33008-18.

  • 43. Kawai-Kowase, K., et al., PIAS1 activates the expression of smooth muscle cell differentiation marker genes by interacting with serum response factor and class I basic helix-loop-helix proteins. Mol Cell Biol, 2005. 25(18): p. 8009-23.

  • 44. Megidish, T., J. H. Xu, and C. W. Xu, Activation of p53 by protein inhibitor of activated Stat1 (PIAS1). J Biol Chem, 2002. 277(10): p. 8255-9.

  • 45. Chodniewicz, D. and D. V. Zhelev, Novel pathways of F-actin polymerization in the human neutrophil. Blood, 2003. 102(6): p. 2251-8.

  • 46. Inoue, N., et al., Cyclin-dependent kinase inhibitor, p21WAF1/CIP1, is involved in adipocyte differentiation and hypertrophy, linking to obesity, and insulin resistance. J Biol Chem, 2008. 283(30): p. 21220-9.

  • 47. Kaneto, H., et al., Oxidative stress induces p21 expression in pancreatic islet cells: possible implication in beta-cell dysfunction. Diabetologia, 1999. 42(9): p. 1093-7.

  • 48. Lim, G. E., et al., The rho guanosine 5′-triphosphatase, cell division cycle 42, is required for insulin-induced actin remodeling and glucagon-like peptide-1 secretion in the intestinal endocrine L cell. Endocrinology, 2009. 150(12): p. 5249-61.

  • 49. Sumitani, S., et al., Akt1 and Akt2 differently regulate muscle creatine kinase and myogenin gene transcription in insulin-induced differentiation of C2C12 myoblasts. Endocrinology, 2002. 143(3): p. 820-8.

  • 50. Yoshizaki, T., et al., Myosin 5a is an insulin-stimulated Akt2 (protein kinase Bbeta) substrate modulating GLUT4 vesicle translocation. Mol Cell Biol, 2007. 27(14): p. 5172-83.

  • 51. Takeshita, Y., et al., Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line. Metabolism, 2006. 55(11): p. 1464-72.

  • 52. Hansotia, T., et al., Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest, 2007. 117(1): p. 143-52.

  • 53. Utviklingen i norsk kosthold. Vol. 2008, Utviklingen i norsk kosthold 2008., Oslo: Direktoratet, 2008. 27 s.

  • 54. Greene, C. S., D. S. Himmelstein, and J. H. Moore, A Model Free Method to Generate Human Genetics Datasets with Complex Gene-Disease Relationships. Lect Notes Comput Sci, 2010. 6023(LNCS): p. 74-85.



All references cited herein, are hereby incorporated by reference. Sequences of the single nucleotide polymorphisms cited by the accession numbers herein, are hereby incorporated by reference and can be found at www.ncbi.nlm.nih.gov/sites/entrez or snpper.chip.org/bio, among other sites, using the accession numbers provided.


Tables









TABLE 1







Biological functions and diseases related to the SNPs that


showed highest association with HOMA2 IR. The genes


linked to the SNPs in the ref-SNP selection Top 100 lists


were compared with the genes linked with the SNPs on the


Metabochip. Significantly enriched IPA defined functions and


diseases, according IPA's Functional Analysis, are listed


(FDR < 0.01). The table also shows the number of genes


related to the functions, linked with the SNPs in the ref-SNP


selection Top 100 lists for the AHC6-AHC0 and the BMC6-BMC0


comparisons separately.











All Top 100 lists
AHC
BMC











Function Annotation
P-value
# genes
# genes
# genes














diabetes mellitus
5.17E−13
63
15
23


T2D
6.39E−13
47
10
20


endocrine system disorder
1.68E−12
64

24


metabolic disorder
3.48E−12
67
16
24


cardiovascular disorder
6.46E−10
58
20
17


hypertension
8.65E−09
35
12



atherosclerosis
4.56E−08
38
13



genetic disorder
4.56E−08
102
27
35


coronary artery disease
5.01E−08
36
12
12


T1D
1.80E−07
33
11



autoimmune disease
8.59E−07
50
17
16


immunological disorder
1.96E−06
54
18
17


amyotrophic lateral sclerosis
1.53E−05
21
 6
10


progressive motor neuropathy
1.68E−05
31
11



Crohn's disease
5.41E−05
29

11


neurological disorder
6.55E−05
66
19
26


rheumatoid arthritis
1.50E−04
35
13
10


digestive system disorder
2.48E−04
33

12


inflammatory disorder
5.16E−04
53
17



Alzheimer's disease
9.78E−04
23
 6
10


skeletal and muscular disorder
1.80E−03
51
18
15


rheumatic disease
1.93E−03
36




connective tissue disorder
2.23E−03
37
14



Parkinson's disease
5.24E−03
17
 7

















TABLE 2







Pairs of associations between SNP and the gene expression values in nearest gene in


the gene-SNP selection Top100 lists. Pairs in which are included, the gene is related to


insulin resistance/T2D in at least one PubMed entry, and there is at least one significant


(FDR < 0.05, value typed in bold) genotype specific gene expression change (log2-ratio) for


one of the four comparisons, and a GenTrainScore > 0.750.

















Nearest
# PubMed




Nucleotide
Chitest100
GenTrain


Comparison
Gene
citations
SNP
Frequency
Log2-ratio
FDR
Substitution
(p)
Score



















AHC6-AHC0
PDZD2

rs283122



C → T
0.099
0.866





CC
1
NA
NA








CT
11
0.059

0.036









TT
18
−0.031
0.086









TPM1
1
rs17752921



T → C
0.291
0.850





TT
27
−0.123

<0.001









CT
3
0.122
0.378









LPA
9
rs6415084



T → C
0.055
0.838





CC
6
0.016
0.801








CT
18
0.019
0.307








TT
6
−0.127

0.039










NME1
1
rs2302254



C → T
0.234
0.769





CC
23
−0.058
0.108








CT
7
0.126

0.042










ADRA1A
1
rs4732874



T → C
0.462
0.879





CC
17
−0.070
0.031








CT
10
0.070
0.108








TT
3
−0.027
0.431









ARHGEF11
3
rs822570



T → C
0.030
0.927





CC
11
−0.061
0.417








CT
12
0.229

0.005









TT
7
0.012
0.910









SIK3
1
rs888246



C → T
0.463
0.838





CC
25
−0.084
0.130








CT
5
−0.429

0.031










TMEM195
1
rs7781413



A → G
0.943
0.869





AA
21
−0.036

0.021









AG
8
0.057
0.280








GG
1
NA
NA









ADCY9
1
rs2532007



G → A
0.424
0.856





AA
24
0.038
0.312








AG
6
−0.226
0.184









SLC2A1
6
rs751210



G → A
0.051
0.808





AA
1
NA
NA








AG
14
−0.110
0.328








GG
15
−0.513

0.002










PLTP
9
rs435306



T → G
0.495
0.847





AA
19
−0.039
0.048








AC
9
0.047
0.180








CC
2
NA
NA











rs378114



C → T
0.495
0.904





AA
2
NA
NA








AG
9
0.047
0.180








GG
19
−0.039

0.048









BMC6-BMC0
CAMTA1
1
rs6577435



C → A
0.440
0.873





AA
1
NA
NA








AC
10
0.105
0.232








CC
21
−0.117

0.009










CACNA1G
1
rs989128



G → A
0.012
0.785





AA
6
−0.017
0.513








AG
10
−0.081

0.028









GG
16
0.013
0.323









SULF2
1
rs6125103



C → T
0.203
0.837





CC
22
0.210

0.011









CT
9
−0.128
0.220








TT
1
NA
NA








BMC6-AHC6
ITGAV
1
rs3738919



C → A
0.595
0.925





AA
8
0.515

0.032









AC
14
−0.018
0.764








CC
10
−0.060
0.657









SULF2
1
rs11699888



C → T
0.421
0.862





CC
27
−0.054
0.294








CT
5
0.359
0.039









FIGURE LEGENDS


FIG. 1 Changes in HOMA2 IR or protein concentration (log2-ratio), separately for each comparison, and genotype for the SNPs indicated. GenTrain score>0.73 for all SNPs (A-D). The SNP rs2291726 (D) deviated from HWE (P<0.05).



FIG. 2 Unsupervised hierarchical clustering (Manhattan distance measures, complete linkage) of the Top100 SNPs (rows) associated with change in HOMA2 IR in response to A) the AHC diet, and B) the BMC diet. The subjects (columns) are sorted by HOMA2 IR change, increasing from left to right. SNPs within the right hand side brackets of the heatmaps are identified in the ref-SNP selection Top100 lists in Supplementary table 1-4.



FIG. 3 A) Hierarchical clustering showing distance between subjects based on genotype information from the 71 061 SNPs (Manhattan distance measures, complete linkage). B) PCA plot based on the same data, showing the 3 first principal components.









SUPPLEMENTARY TABLE 1







Ref-SNP selection Top 100 list, AHC6-AHC0












SNP
Nearest Gene
ANOVA p-value
GenTrain Score
ChiTest100
Cluster















rs16961756

<0.001
0.736
0.421
B


rs29095
VAPA
<0.001
0.875
0.657
B


rs7237794
VAPA
<0.001
0.843
0.688
B


rs917688

<0.001
0.738
0.657
B


rs10803976

<0.001
0.885
0.463
A


rs780242

<0.001
0.904
0.091
A


rs16914660
ANK3
<0.001
0.842
0.667
A


rs7600698

<0.001
0.507
0.362


rs17236914

<0.001
0.845
0.072
B


rs6753302
EPAS1
<0.001
0.837
<0.001
B


rs11858742
ZWILCH
<0.001
0.832
0.354
B


rs11031821

<0.001
0.901
0.152
A


rs6445062

<0.001
0.877
0.067


rs4646400
PEMT
<0.001
0.798
0.463
A


rs3828760
FAM46A
<0.001
0.885
0.004
B


rs1390785
GALNTL6
<0.001
0.901
0.742
A


rs10509771
CCDC147
<0.001
0.891
0.004
A


rs2480

<0.001
0.912
0.511


rs968371
CSMD1
<0.001
0.811
0.670
A


rs13176923

<0.001
0.751
0.657
B


rs13189446

<0.001
0.824
0.688
B


rs7243663
L3MBTL4
<0.001
0.771
0.688
B


rs17501809
C9orf46
<0.001
0.804
0.352
B


rs11038913
AMBRA1
<0.001
0.841
0.163
B


rs17401147

<0.001
0.885
0.073
B


rs42495
SEMA5A
<0.001
0.915
0.857


rs10972856

<0.001
0.777
0.234
B


rs11570115
MYBPC3
<0.001
0.888
0.144
B


rs4579523

<0.001
0.802
<0.001


rs7101470
C11orf49
<0.001
0.917
0.655
B


rs10838651
C11orf49
<0.001
0.903
0.655
A


rs16843307

<0.001
0.936
0.073
B


rs12666730

<0.001
0.897
0.857


rs2362311
ABCA13
<0.001
0.826
0.072
A


rs11179215
TRHDE
<0.001
0.898
0.295
B


rs1883414
LOC100294320
0.001
0.929
0.063
A


rs10121339

0.001
0.819
0.421
B


rs4143110

0.001
0.935
0.424
B


rs12973523
FCER2
0.001
0.771
0.425


rs12486603
MYRIP
0.001
0.914
0.011
A


rs7071851
PTCHD3
0.001
0.893
0.523


rs2817644

0.001
0.816
0.574
B


rs6902530

0.001
0.784
0.657
B


rs10483213
CENPM
0.001
0.767
0.495
B


rs11700328
ANGPT4
0.001
0.784
0.425


rs16824470

0.001
0.911
0.863


rs815811
C2orf61
0.001
0.795
0.144


rs2350623
C22orf9
0.001
0.889
0.285


rs10242065

0.001
0.830
0.018


rs13227663

0.001
0.860
0.027


rs7836548

0.001
0.864
0.109
B


rs11790360

0.001
0.811
0.474


rs2262933
SMYD3
0.001
0.863
0.526


rs685897

0.001
0.835
0.846
A


rs4239424

0.001
0.712
0.001


rs1409570

0.001
0.695
0.185


rs7897931

0.001
0.836
0.339


rs11022039

0.001
0.873
0.523


rs7553849
PRDM16
0.001
0.750
0.079
A


rs2569430
CTU1
0.001
0.778
0.015


rs4994351
ZNF331
0.001
0.741
0.049


rs12366082
DSCAML1
0.001
0.746
0.290
B


rs1918611
ABCA13
0.001
0.872
0.268
A


rs6871607

0.001
0.865
0.574
B


rs11649247
WWOX
0.001
0.707
0.462
A


rs17722827

0.001
0.754
0.421
B


rs17766326
SLC25A21
0.001
0.863
0.495
B


rs5999900

0.001
0.713
0.354
B


rs1885750

0.001
0.724
0.162
A


rs12504564
TMEM144
0.001
0.826
0.058


rs182390

0.001
0.896
0.495
A


rs10153481
ZNF709
0.001
0.682
0.002


rs17706149
NUP35
0.001
0.876
0.290
B


rs7138803

0.001
0.854
0.041
A


rs10928303

0.001
0.858
0.291
B


rs1437848
GALNTL6
0.001
0.907
0.354
B


rs2010014

0.001
0.879
0.352
B


rs221020
PAK7
0.001
0.915
0.667
A


rs10916785

0.001
0.741
0.001


rs270413
BMP6
0.001
0.826
0.146
A


rs1297215
NRIP1
0.001
0.910
0.064
A


rs2253231
NRIP1
0.001
0.912
0.064
A


rs7729395

0.001
0.876
0.185


rs2242104
VLDLR
0.001
0.894
0.189
A


rs767145

0.001
0.808
0.835
A


rs739571

0.001
0.901
0.336
A


rs17668126

0.001
0.797
0.336


rs2432761
FARS2
0.002
0.913
0.672


rs3751544
MEIS2
0.002
0.885
0.425
A


rs6663310

0.002
0.756
0.001


rs4311480
FILIP1
0.002
0.890
0.830


rs2241733
PLXNA4
0.002
0.763
0.234
B


rs2160706

0.002
0.836
0.225


rs11129948

0.002
0.827
0.600
A


rs6859734
ADAMTS19
0.002
0.863
<0.001
A


rs7380441
ADAMTS19
0.002
0.805
<0.001


rs1319075

0.002
0.820
0.057
A


rs7382112

0.002
0.906
0.019
A


rs9393921

0.002
0.880
0.021


rs9885928

0.002
0.820
0.057
















SUPPLEMENTARY TABLE 2







Ref-SNP selection Top100 list, BMC6-BMC0















GenTrain




SNP
Nearest Gene
ANOVA p-value
Score
ChiTest100
Cluster















rs2623763

<0.001
0.670
0.088



rs4712572
CDKAL1
<0.001
0.760
0.062


rs1993919
STAB2
<0.001
0.881
0.144
D


rs7536825
KIF26B
<0.001
0.846
0.131
C


rs16960303
CDH13
<0.001
0.903
0.142


rs9902569

<0.001
0.922
0.667
E


rs13244124
CDK14
<0.001
0.819
0.018
D


rs6052937
SLC23A2
<0.001
0.884
<0.001
E


rs12359453

<0.001
0.789
0.742
D


rs6069099

<0.001
0.837
0.285


rs17620466

<0.001
0.738
0.495
D


rs9961435

<0.001
0.788
0.162
E


rs875294

<0.001
0.815
0.234
C


rs4465666

<0.001
0.606
<0.001
C


rs11912637

<0.001
0.883
0.268


rs10431808
CLN6
<0.001
0.822
0.888


rs6494711
PIAS1
<0.001
0.924
0.888
C


rs4895769

<0.001
0.887
0.225
E


rs11855184
DMXL2
<0.001
0.897
0.049
E


rs10512215

<0.001
0.899
0.526


rs13122545
FAM190A
<0.001
0.892
0.291
D


rs9466015

<0.001
0.917
0.742
D


rs955010
FAM190A
<0.001
0.916
0.290
D


rs4704320
IQGAP2
<0.001
0.877
0.399
E


rs3807689
MAGI2
<0.001
0.818
0.672
D


rs4650540

<0.001
0.930
0.260


rs13356198
CHSY3
<0.001
0.875
0.440


rs6463750

<0.001
0.855
0.027


rs257215

<0.001
0.875
0.009


rs257221

<0.001
0.858
0.009


rs3746532
LOC100287002
0.001
0.673
0.508


rs11107935
NAV3
0.001
0.916
0.352
D


rs1359292
CCDC30
0.001
0.737
0.290
D


rs10896450

0.001
0.838
0.595


rs4620729

0.001
0.802
0.318
E


rs7947353

0.001
0.902
0.595
E


rs6706382

0.001
0.877
0.244


rs17047703
TGFB2
0.001
0.801
0.871


rs11581605
TGFB2
0.001
0.924
0.871


rs7950547

0.001
0.840
0.828


rs10793139

0.001
0.824
0.799


rs12742404
CAMSAP1L1
0.001
0.951
0.073
D


rs2292096
CAMSAP1L1
0.001
0.902
0.073
D


rs2514801
CDH17
0.001
0.875
0.349


rs2338545
PLB1
0.001
0.810
0.440


rs11675205
TCF7L1
0.001
0.918
0.614


rs4710944
CDKAL1
0.001
0.884
0.244


rs627522
ZNF708
0.001
0.894
0.724


rs4774183

0.001
0.507
<0.001


rs12065336

0.001
0.728
0.290
D


rs950692
GPR98
0.001
0.751
0.234
D


rs11712666
VGLL4
0.001
0.733
0.131


rs12546518
GRHL2
0.001
0.808
0.152


rs3091317

0.001
0.903
0.899


rs3091321
CCL7
0.001
0.901
0.863


rs12891473
SRP54
0.001
0.698
0.001


rs6989246
MYOM2
0.001
0.815
0.943
E


rs11871821

0.001
0.685
<0.001


rs17746008
PHLPP1
0.001
0.895
0.502
D


rs1799977
MLH1
0.001
0.936
0.614


rs807013

0.001
0.693
0.003


rs1907415

0.001
0.935
0.526


rs7616047

0.001
0.886
0.146


rs10735653

0.001
0.829
<0.001
E


rs2590174

0.001
0.861
0.924
C


rs35879596
GRAMD1A
0.001
0.887
0.440
E


rs4290308

0.001
0.822
0.042
C


rs1432226
THSD7B
0.001
0.804
0.075


rs11042902
MRVI1
0.001
0.872
0.459


rs979015

0.001
0.807
0.137
C


rs4555526

0.001
0.910
0.017


rs2425463
CHD6
0.001
0.821
0.036


rs17637580
LARS2
0.001
0.822
0.015
E


rs10465729

0.001
0.833
0.011


rs10038804
UGT3A2
0.001
0.865
0.320


rs2038431
ZFP64
0.001
0.726
0.943


rs7604914
FAM82A1
0.001
0.898
0.916


rs3900452

0.001
0.762
0.195


rs4016189

0.001
0.890
0.195
C


rs2159894

0.001
0.773
0.672


rs17674590

0.001
0.811
0.295
E


rs1156619

0.001
0.912
0.244


rs922453

0.001
0.882
0.667
E


rs654126
CSMD1
0.001
0.909
0.108


rs6927578
PARK2
0.001
0.815
0.463
D


rs11950170

0.001
0.849
0.421
D


rs16823728
C2orf83
0.001
0.776
0.688
D


rs17633078
KATNAL1
0.001
0.883
0.502
D


rs277315

0.001
0.736
0.502
D


rs9562933

0.001
0.864
0.042


rs716453
PPAPDC1A
0.001
0.731
0.657
D


rs7686154

0.001
0.865
0.023
D


rs7968178

0.001
0.911
0.657
D


rs226236
LASP1
0.001
0.804
0.177


rs2943599

0.001
0.869
0.318


rs10853522

0.001
0.906
0.924
E


rs192671
CCDC50
0.001
0.881
0.441
E


rs6502774
TUSC5
0.001
0.808
0.268


rs4905899
EML1
0.001
0.788
0.001


rs2028210
AMPH
0.001
0.890
0.672
















SUPPLEMENTARY TABLE 3







Ref-SNP selection Top100 list, BMC6-AHC6












Nearest
ANOVA p-
GenTrain



SNP
Gene
value
Score
ChiTest100














rs12304001

<0.001
0.826
0.399


rs17236914

<0.001
0.845
0.072


rs6753302
EPAS1
<0.001
0.837
<0.001


rs16916966

<0.001
0.878
0.001


rs1556260
USF1
<0.001
0.918
0.005


rs7597683

<0.001
0.814
0.094


rs7160372

<0.001
0.804
0.267


rs7196505

<0.001
0.849
0.225


rs1996806
RGS7
<0.001
0.881
0.462


rs11558471
SLC30A8
<0.001
0.906
0.846


rs9296579

<0.001
0.808
<0.001


rs12468863
KCNK3
<0.001
0.834
0.295


rs1275941

<0.001
0.855
0.549


rs3739081

<0.001
0.940
0.549


rs6859734
ADAMTS19
<0.001
0.863
<0.001


rs7380441
ADAMTS19
<0.001
0.805
<0.001


rs10220965

<0.001
0.756
0.109


rs1488666

<0.001
0.693
0.506


rs2781792

<0.001
0.741
0.185


rs17069214

<0.001
0.931
0.203


rs17245857

<0.001
0.827
0.055


rs7553849
PRDM16
<0.001
0.750
0.079


rs2235642
IFT140
<0.001
0.694
0.667


rs3758376
SEC61A2
<0.001
0.836
0.116


rs2305413
CHRNA1
<0.001
0.909
0.424


rs12903587
CHD2
<0.001
0.853
0.393


rs2062096

<0.001
0.938
<0.001


rs12467466
CENPA
<0.001
0.754
0.362


rs3802177
SLC30A8
<0.001
0.932
0.672


rs11179215
TRHDE
<0.001
0.898
0.295


rs2399786
NUDT5
<0.001
0.910
0.659


rs6744164

0.001
0.812
0.421


rs968371
CSMD1
0.001
0.811
0.670


rs13266634
SLC30A8
0.001
0.881
0.914


rs7855478
MORN5
0.001
0.692
0.109


rs12424799

0.001
0.773
0.080


rs12891948

0.001
0.754
0.320


rs17801467

0.001
0.840
0.290


rs929269
ENDOU
0.001
0.727
0.421


rs281385
MAMSTR
0.001
0.721
0.290


rs12964419

0.001
0.919
0.871


rs2274305
DCDC2
0.001
0.862
0.290


rs488078

0.001
0.869
0.548


rs10947465

0.001
0.805
0.393


rs17484283

0.001
0.785
0.001


rs12982980
ZNF468
0.001
0.638
0.022


rs4466385
C8orf34
0.001
0.881
0.067


rs17736747

0.001
0.849
0.295


rs4644227
C8orf34
0.001
0.863
0.511


rs17635121

0.001
0.934
0.019


rs1674091
DTX1
0.001
0.689
0.080


rs472972
POLN
0.001
0.825
0.421


rs1487775

0.001
0.862
0.295


rs2072844

0.001
0.872
0.062


rs1861699

0.001
0.874
0.587


rs3788464
SYN3
0.001
0.873
0.657


rs942024

0.001
0.752
0.672


rs12973523
FCER2
0.001
0.771
0.425


rs11964281
ESR1
0.001
0.771
0.421


rs7025024

0.001
0.795
0.549


rs12683791

0.001
0.936
0.030


rs7862653

0.001
0.779
0.349


rs870535

0.001
0.912
0.319


rs7944972
OPCML
0.001
0.852
0.002


rs582669
PKHD1
0.001
0.927
0.637


rs13116006

0.001
0.867
0.614


rs1424790

0.001
0.830
0.020


rs1625560

0.001
0.898
0.614


rs3777102
NRG2
0.001
0.777
0.857


rs912377

0.001
0.807
0.891


rs13220430
EYS
0.001
0.819
0.422


rs1363472
KIAA1024L
0.001
0.836
<0.001


rs171895

0.001
0.934
0.041


rs9592493
PCDH9
0.001
0.829
0.586


rs468471
RCL1
0.001
0.350
0.554


rs2338871
LCP2
0.001
0.741
0.143


rs2830957

0.001
0.883
0.586


rs17718358

0.001
0.754
0.574


rs9645497

0.001
0.815
0.688


rs6777976
OXNAD1
0.001
0.783
0.225


rs38478

0.001
0.847
0.320


rs763842

0.002
0.920
0.339


rs12413154
RHOBTB1
0.002
0.567
0.050


rs6995157

0.002
0.574
0.388


rs10163354
ABCC11
0.002
0.919
<0.001


rs2504927
SLC22A3
0.002
0.890
0.523


rs13424541
ZNF638
0.002
0.869
0.574


rs3176295
FGF17
0.002
0.751
0.574


rs17479629
MICAL2
0.002
0.903
0.657


rs9815875

0.002
0.752
0.349


rs2807304
TLE4
0.002
0.801
0.422


rs11772485

0.002
0.740
0.058


rs17098621

0.002
0.822
0.755


rs2063777

0.002
0.797
0.672


rs10830089

0.002
0.773
0.399


rs3766509
ACP6
0.002
0.846
0.778


rs7267327

0.002
0.856
0.639


rs17150506
CSNK1G3
0.002
0.910
0.336


rs2112468
CSNK1G3
0.002
0.912
0.506


rs4546375
CSNK1G3
0.002
0.900
0.336
















SUPPLEMENTARY TABLE 4







Ref-SNP selection Top100 list, (BMC6-BMC0)-(AHC6-AHC0)













ANOVA p-
GenTrain



SNP
Nearest Gene
value
Score
ChiTest100














rs2480

<0.001
0.912
0.511


rs1704405
EHD4
<0.001
0.757
0.586


rs7071851
PTCHD3
<0.001
0.893
0.523


rs204925
LMO1
<0.001
0.817
0.004


rs11916112
ARHGEF3
<0.001
0.813
0.007


rs11041982
STK33
<0.001
0.882
0.058


rs7538377
PCNXL2
<0.001
0.788
0.778


rs1409570

<0.001
0.695
0.185


rs17138899
ACACA
<0.001
0.907
0.354


rs2302803
ACACA
<0.001
0.879
0.354


rs993743

<0.001
0.853
0.080


rs11187169

<0.001
0.810
0.586


rs4712572
CDKAL1
<0.001
0.760
0.062


rs13176923

<0.001
0.751
0.657


rs13189446

<0.001
0.824
0.688


rs10017447

<0.001
0.789
0.001


rs11101387
ARHGAP22
<0.001
0.808
0.149


rs11213776

<0.001
0.800
0.037


rs1502275

<0.001
0.727
0.424


rs17095168

<0.001
0.743
0.421


rs10833451
NELL1
0.001
0.729
<0.001


rs6047259

0.001
0.818
0.891


rs807013

0.001
0.693
0.003


rs9523880

0.001
0.943
0.079


rs968371
CSMD1
0.001
0.811
0.670


rs11783921

0.001
0.855
0.574


rs3104917

0.001
0.844
0.502


rs3887267
C9orf3
0.001
0.868
0.688


rs11695576

0.001
0.754
0.407


rs11193140
SORCS1
0.001
0.691
0.163


rs3744589
ACACA
0.001
0.945
0.495


rs7729395

0.001
0.876
0.185


rs7660651

0.001
0.929
0.203


rs11070879
MAPK6
0.001
0.921
0.399


rs16843307

0.001
0.936
0.073


rs758504
NFIC
0.001
0.795
0.502


rs7897931

0.001
0.836
0.339


rs4810347

0.001
0.825
0.506


rs11590511

0.001
0.817
0.001


rs1860904

0.001
0.856
0.011


rs7677806

0.001
0.882
0.011


rs2460968
SAMD12
0.001
0.805
0.079


rs10093536

0.001
0.884
0.667


rs10803976

0.001
0.885
0.463


rs10242065

0.001
0.830
0.018


rs13227663

0.001
0.860
0.027


rs6748854

0.001
0.807
0.011


rs12666730

0.001
0.897
0.857


rs3828760
FAM46A
0.001
0.885
0.004


rs654126
CSMD1
0.001
0.909
0.108


rs7106565

0.001
0.879
0.891


rs4579523

0.001
0.802
<0.001


rs10933436

0.001
0.770
0.339


rs11693862

0.001
0.776
0.339


rs9558407

0.001
0.816
0.003


rs10463168

0.001
0.911
0.659


rs6502774
TUSC5
0.001
0.808
0.268


rs1546208

0.001
0.908
0.421


rs3735444
MAGI2
0.001
0.806
0.285


rs1721073

0.001
0.910
0.399


rs963080

0.001
0.913
0.399


rs3811976
SLCO4C1
0.001
0.771
0.943


rs6891076

0.001
0.887
0.943


rs10929308
HEATR7B1
0.001
0.934
0.595


rs353747

0.001
0.840
0.336


rs12891473
SRP54
0.001
0.698
0.001


rs6951227
MAGI2
0.001
0.849
0.088


rs6663310

0.001
0.756
0.001


rs7127684
STK33
0.001
0.897
0.024


rs13324043

0.001
0.792
0.463


rs11638978

0.001
0.829
0.799


rs10124300

0.001
0.784
0.042


rs16914660
ANK3
0.001
0.842
0.667


rs12492974

0.001
0.778
0.234


rs16838912

0.001
0.760
0.234


rs13028683
CDKL4
0.001
0.793
0.424


rs1018966
CTNND2
0.001
0.924
0.012


rs17318596
ATP5SL
0.001
0.608
<0.001


rs4674
BCKDHA
0.001
0.811
<0.001


rs3118942
LPPR1
0.001
0.838
0.027


rs6548940

0.001
0.785
0.093


rs6753302
EPAS1
0.001
0.837
<0.001


rs236004

0.001
0.825
0.006


rs2413923
SHC4
0.001
0.894
0.586


rs10774811

0.001
0.847
0.094


rs828999
SLC25A24
0.001
0.934
0.828


rs4787016
A2BP1
0.001
0.789
0.093


rs17545182

0.001
0.770
0.039


rs17236914

0.001
0.845
0.072


rs7243663
L3MBTL4
0.001
0.771
0.688


rs12735509

0.001
0.875
0.463


rs12065336

0.001
0.728
0.290


rs9918378

0.001
0.785
0.185


rs4236002
CDKAL1
0.001
0.931
0.336


rs12619647
SEPT2
0.001
0.819
0.914


rs7313017
LOC100130825
0.001
0.512
0.021


rs9644620
LOC100128993
0.001
0.920
0.672


rs2599547

0.002
0.902
0.137


rs974312

0.002
0.748
0.495


rs6573513
PPP2R5E
0.002
0.854
0.049
















SUPPLEMENTARY TABLE 5







Gene-SNP selection Top100 list, AHC6-AHC0












Nearest
ANOVA p-




SNP
Gene
value
GenTrainScore
ChiTest100














rs6802942
PPP2R3A
<0.001
0.891
0.495


rs6513775
PTPRT
<0.001
0.776
0.088


rs4767020
RPH3A
<0.001
0.743
0.495


rs9863749
C3orf20
<0.001
0.854
0.421


rs6035839
XRN2
<0.001
0.891
0.422


rs6082384
XRN2
<0.001
0.937
0.422


rs10982661
TMOD1
<0.001
0.838
0.143


rs10071707
PDZD2
<0.001
0.919
0.587


rs17817463
DISC1
<0.001
0.733
0.421


rs283122
PDZD2
<0.001
0.866
0.099


rs6959021
PKD1L1
<0.001
0.864
0.268


rs9639988
PKD1L1
<0.001
0.819
0.268


rs2345122
ZKSCAN2
<0.001
0.824
0.285


rs13047833
DSCAM
<0.001
0.906
0.354


rs4871031
DEPDC6
<0.001
0.833
0.225


rs2371438
ERBB4
<0.001
0.893
0.502


rs940539
CDC2L6
<0.001
0.823
0.185


rs10120342
PLAA
<0.001
0.928
<0.001


rs2836416
ERG
0.001
0.830
0.857


rs17826507
PHC3
0.001
0.791
0.080


rs17752921
TPM1
0.001
0.850
0.291


rs2186716
ST3GAL4
0.001
0.760
0.574


rs9612266
BCR
0.001
0.897
0.830


rs9559759
COL4A1
0.001
0.923
0.001


rs11755592
ZFAND3
0.001
0.807
<0.001


rs3128
CTSH
0.001
0.802
0.023


rs2920836
FRS2
0.001
0.895
0.042


rs4785187
ZNF423
0.001
0.841
0.871


rs7599195
OSBPL6
0.001
0.837
0.463


rs7559527
OSBPL6
0.001
0.919
0.463


rs306410
ATP8A2
0.001
0.931
0.463


rs408359
AGPAT1
0.001
0.887
0.162


rs7386
C11orf48
0.001
0.523
0.075


rs1326270
PTPRC
0.001
0.808
0.339


rs765719
ALDH6A1
0.001
0.921
0.005


rs2518523
OR6K6
0.001
0.765
<0.001


rs16841047
OR6K6
0.001
0.937
<0.001


rs1124922
HIP1
0.001
0.768
0.688


rs2071487
GSTM1
0.001
0.591
<0.001


rs2071487
GSTM1
0.001
0.591
<0.001


rs6415084
LPA
0.001
0.838
0.055


rs4146673
ALK
0.001
0.902
0.835


rs8051232
COQ7
0.001
0.831
0.871


rs11759825
PACSIN1
0.001
0.773
0.285


rs12991495
DNMT3A
0.001
0.821
0.393


rs6984210
BMP1
0.002
0.819
0.072


rs634370
ABI3
0.002
0.745
0.802


rs2236862
GSTM1
0.002
0.464
<0.001


rs2076109
APOBEC3F
0.002
0.614
0.064


rs11637984
SQRDL
0.002
0.583
0.007


rs2302254
NME1
0.002
0.769
0.234


rs10034673
GPRIN3
0.002
0.759
0.657


rs16962458
NECAB2
0.002
0.786
0.943


rs13225749
PTPRZ1
0.002
0.845
0.502


rs4732874
ADRA1A
0.002
0.879
0.462


rs1631117
DNAH8
0.002
0.842
0.463


rs17062130
GPM6A
0.002
0.719
0.789


rs7098200
ADK
0.002
0.931
0.195


rs7725698
MCTP1
0.002
0.781
0.170


rs3743936
MMP25
0.002
0.703
0.657


rs6141443
RALY
0.002
0.658
0.109


rs7188014
LITAF
0.002
0.778
0.916


rs4558548
PPP1CB
0.002
0.915
0.441


rs3748229
PIK3AP1
0.002
0.770
0.285


rs989128
CACNA1G
0.002
0.785
0.012


rs8129934
ADARB1
0.002
0.835
0.495


rs6950693
PTPRN2
0.002
0.572
0.034


rs7557817
FHL2
0.002
0.827
0.422


rs10486293
HDAC9
0.002
0.941
0.036


rs17705427
DNAJC24
0.002
0.913
0.177


rs296886
HNRNPK
0.002
0.881
0.755


rs822570
ARHGEF11
0.002
0.927
0.030


rs17294592
SVIL
0.002
0.729
0.574


rs888246
KIAA0999
0.002
0.838
0.463


rs28528975
GAL3ST2
0.002
0.787
0.393


rs2240191
RPH3A
0.002
0.825
0.014


rs2236862
GSTM1
0.002
0.464
<0.001


rs2401035
CCDC59
0.002
0.887
0.755


rs12829066
ITPR2
0.003
0.811
0.639


rs1560489
GPRIN3
0.003
0.902
0.268


rs8117456
KIF16B
0.003
0.882
0.657


rs7766388
WDR27
0.003
0.849
0.424


rs520328
DSCAML1
0.003
0.780
0.463


rs926561
AKAP12
0.003
0.827
0.128


rs10516471
PPP3CA
0.003
0.923
0.846


rs13376677
VAV3
0.003
0.875
0.319


rs882422
PCSK6
0.003
0.896
0.657


rs7714610
FSTL4
0.003
0.727
0.143


rs3809449
FAM177A1
0.003
0.660
0.040


rs2523190
GNAI1
0.003
0.804
0.234


rs6556312
RGS14
0.003
0.706
0.586


rs12761450
ANK3
0.003
0.890
0.778


rs7781413
TMEM195
0.003
0.869
0.943


rs2532007
ADCY9
0.003
0.856
0.424


rs814528
SPTBN4
0.003
0.778
0.079


rs10929587
ADAM17
0.003
0.851
0.011


rs10495563
ADAM17
0.003
0.752
0.011


rs2382553
C9orf93
0.003
0.891
0.285


rs221797
GIGYF1
0.003
0.884
0.203


rs6963037
C7orf10
0.003
0.805
0.352
















SUPPLEMENTARY TABLE 6







Gene-SNP selection Top100 list, BMC6-BMC0












Nearest
ANOVA p-




SNP
Gene
value
GenTrainScore
ChiTest100














rs7591006
SPAG16
<0.001
0.930
0.655


rs151290
KCNQ1
<0.001
0.762
0.463


rs12624282
C2orf43
<0.001
0.897
0.144


rs2102472
LBH
<0.001
0.810
0.349


rs6850131
HSD17B13
<0.001
0.850
0.057


rs11735092
HSD17B13
<0.001
0.842
0.164


rs1965869
FAM13A
<0.001
0.916
0.441


rs12718455
SNTG2
<0.001
0.837
0.511


rs3132680
TRIM31
<0.001
0.919
0.960


rs9827210
CNTN4
<0.001
0.880
0.888


rs10451237
RICH2
<0.001
0.736
0.587


rs12433712
SRP54
<0.001
0.922
0.891


rs7775864
SNX14
<0.001
0.882
0.425


rs6909767
SNX14
<0.001
0.942
0.425


rs7771612
SNX14
<0.001
0.927
0.425


rs7742691
SNX14
<0.001
0.862
0.425


rs6463016
PRKAR1B
<0.001
0.769
0.502


rs12184386
CUL2
<0.001
0.891
0.267


rs17126706
CPNE8
<0.001
0.840
0.234


rs7224186
ARSG
<0.001
0.811
0.657


rs3129294
HLA-DPB2
<0.001
0.803
0.141


rs13072512
FOXP1
<0.001
0.862
0.474


rs1883414
HLA-DPB2
<0.001
0.929
0.063


rs6577435
CAMTA1
<0.001
NA
0.440


rs6713506
FBXO11
<0.001
0.822
0.871


rs9392366
GMDS
<0.001
0.843
0.421


rs11219462
VWA5A
<0.001
0.897
0.495


rs6454472
SNX14
0.001
0.942
0.549


rs9444352
SNX14
0.001
0.892
0.549


rs2858996
HFE
0.001
0.896
0.441


rs707889
HFE
0.001
NA
0.441


rs989128
CACNA1G
0.001
0.785
0.012


rs1965869
FAM13A
0.001
0.916
0.441


rs7004524
CSMD1
0.001
0.849
0.018


rs3118860
DAPK1
0.001
0.844
0.526


rs12034925
DNAH14
0.001
0.838
0.433


rs7189501
A2BP1
0.001
0.843
0.421


rs17533945
MYO9B
0.001
0.817
0.799


rs1323080
C10orf11
0.001
0.820
0.835


rs6775216
SHOX2
0.001
0.856
0.023


rs31872
PCDHA11
0.001
0.822
0.937


rs13213129
LPAL2
0.001
0.577
0.742


rs9282566
ABCC4
0.001
0.782
0.657


rs169250
FLJ25076
0.001
0.792
0.441


rs17170270
TPK1
0.001
0.913
0.495


rs487269
SRGAP3
0.001
0.762
0.290


rs17170134
CNTNAP2
0.001
0.935
0.433


rs11598750
ADARB2
0.001
0.832
0.006


rs370156
LILRB4
0.001
0.794
0.109


rs6125103
SULF2
0.001
0.837
0.203


rs4671052
EHBP1
0.001
0.842
0.291


rs10423215
ZNF347
0.001
0.925
0.290


rs10814381
RNF38
0.001
0.841
0.354


rs10824363
C10orf11
0.001
0.843
0.015


rs6704367
RP1-
0.001
0.900
0.820



21O18.1


rs17623914
PTPRC
0.001
0.921
0.001


rs6935269
C6orf10
0.001
0.867
0.441


rs6594013
ATP2B4
0.001
0.838
0.285


rs2616693
CTNNA3
0.001
0.952
0.587


rs2023945
CCDC46
0.001
0.765
0.742


rs3755930
CTBP1
0.002
0.822
0.599


rs7577342
BRE
0.002
0.841
0.672


rs1902966
BRE
0.002
0.878
0.672


rs12465000
BRE
0.002
0.870
0.672


rs6594013
ATP2B4
0.002
0.838
0.285


rs1062470
CDSN
0.002
0.765
0.667


rs1867996
CDH23
0.002
0.846
0.039


rs16955433
CMIP
0.002
0.720
0.040


rs11667351
BAX
0.002
0.868
0.234


rs1397202
TAC1
0.002
0.910
0.495


rs17789420
NPSR1
0.002
0.769
0.943


rs10149561
FOXN3
0.002
0.830
0.040


rs11574
ID3
0.002
0.848
0.462


rs2664371
MMP16
0.002
0.900
0.600


rs1285882
RREB1
0.002
0.787
0.586


rs2071587
FOXN1
0.002
0.730
0.742


rs10504965
PGCP
0.002
0.895
0.362


rs17035482
PEX14
0.002
0.843
0.495


rs11236172
POLD3
0.002
0.927
0.005


rs17443228
IMMP2L
0.002
0.699
0.657


rs1748356
PDSS1
0.002
0.912
0.195


rs1780179
PDSS1
0.002
0.786
0.195


rs1465314
DTX2
0.002
0.843
0.857


rs13115520
JAKMIP1
0.002
0.750
0.143


rs7780194
BBS9
0.002
0.792
0.011


rs8009944
RAD51L1
0.002
0.767
0.362


rs4843747
BANP
0.002
0.699
0.495


rs6729843
C2orf43
0.002
0.911
0.185


rs340597
C2orf43
0.002
0.756
0.143


rs2246618
MICB
0.002
0.813
0.891


rs2269058
RNF8
0.002
0.806
0.526


rs4235587
ADCY2
0.002
0.731
0.253


rs9912900
SLC39A11
0.002
0.792
0.291


rs1796236
PTPRN2
0.002
0.685
0.040


rs1242787
PTPRN2
0.002
0.812
0.320


rs353644
CD44
0.002
0.870
0.267


rs801712
CERK
0.002
0.807
0.586


rs17270501
RORA
0.002
0.764
0.657


rs9507557
ATP8A2
0.002
0.919
0.177


rs347117
ADAM10
0.003
0.895
0.548
















SUPPLEMENTARY TABLE 7







Gene-SNP selection Top100 list, BMC6-AHC6












Nearest
ANOVA p-




SNP
Gene
value
GenTrainScore
ChiTest100














rs12735646
ARID1A
<0.001
0.783
0.742


rs12726287
ARID1A
<0.001
0.743
0.742


rs10896623
TIMM10
<0.001
0.924
0.058


rs12124339
CAPZB
<0.001
0.752
0.352


rs3738919
ITGAV
<0.001
0.925
0.595


rs151290
KCNQ1
<0.001
0.762
0.463


rs6802942
PPP2R3A
<0.001
0.891
0.495


rs4726075
PRKAG2
<0.001
0.717
0.073


rs11672111
RDH13
<0.001
0.918
0.424


rs12034925
DNAH14
<0.001
0.838
0.433


rs11699888
SULF2
<0.001
0.862
0.421


rs2857107
HLA-DOB
<0.001
0.839
0.143


rs2345122
ZKSCAN2
<0.001
0.824
0.285


rs6775216
SHOX2
<0.001
0.856
0.023


rs12913832
HERC2
<0.001
0.835
0.023


rs9863749
C3orf20
<0.001
0.854
0.421


rs9913412
ALOX15P
<0.001
0.668
0.168


rs1473114
NUDCD3
<0.001
0.881
0.235


rs1800562
HFE
<0.001
0.787
0.004


rs2252551
C6orf106
<0.001
0.928
0.399


rs2814998
C6orf106
<0.001
0.875
0.399


rs13379803
AKAP13
<0.001
0.912
0.295


rs676602
NALCN
<0.001
0.671
0.857


rs13182101
CLTB
<0.001
0.900
0.295


rs7959125
ACSS3
<0.001
0.762
0.424


rs9289121
C3orf30
<0.001
0.816
0.960


rs10889550
LEPR
<0.001
0.817
0.502


rs13213129
LPAL2
0.001
0.577
0.742


rs341397
RORA
0.001
0.765
0.742


rs6704367
RP1-
0.001
0.900
0.820



21O18.1


rs17003153
FRAS1
0.001
0.878
0.463


rs17170270
TPK1
0.001
0.913
0.495


rs6780412
CLDN18
0.001
0.903
0.778


rs4677611
FOXP1
0.001
0.846
0.137


rs555225
ANK1
0.001
0.714
0.742


rs16890723
ANK1
0.001
0.704
0.820


rs2518523
OR6K6
0.001
0.765
0.000


rs16841047
OR6K6
0.001
0.937
0.000


rs13061519
NLGN1
0.001
0.877
0.657


rs2040784
NFE2L3
0.001
0.691
0.136


rs7521047
NUP210L
0.001
0.919
0.846


rs10807151
FKBP5
0.001
0.826
0.058


rs8031186
ADAMTSL3
0.001
0.874
0.109


rs17303530
RORA
0.001
0.920
0.291


rs370156
LILRB4
0.001
0.794
0.109


rs2482424
ABCA1
0.001
0.759
0.290


rs10888977
PPAP2B
0.001
0.837
0.399


rs4808571
MYO9B
0.001
0.731
0.225


rs13217929
SYNJ2
0.001
0.842
0.268


rs17270501
RORA
0.001
0.764
0.657


rs547364
SLC25A24
0.001
0.758
0.799


rs7103581
C11orf49
0.001
0.809
0.637


rs7810512
TBRG4
0.001
0.874
0.141


rs2744957
C6orf106
0.001
0.791
0.094


rs2814992
C6orf106
0.001
0.938
0.094


rs7235783
SPIRE1
0.001
0.934
0.506


rs12516416
AFF4
0.001
0.913
0.422


rs10988495
COL15A1
0.002
0.801
0.354


rs17114699
ANG
0.002
0.820
0.143


rs9726956
FGGY
0.002
0.856
0.029


rs760456
ITGB2
0.002
0.766
0.067


rs2081893
ZNF541
0.002
0.773
0.820


rs12972658
ZNF541
0.002
0.800
0.742


rs12361074
FLJ32810
0.002
0.811
0.502


rs6984210
BMP1
0.002
0.819
0.072


rs11247287
PCSK6
0.002
0.798
0.260


rs17718113
VAT1L
0.002
0.809
0.688


rs1418253
LPHN2
0.002
0.868
0.424


rs367881
LPHN2
0.002
0.874
0.421


rs4491236
NTM
0.002
0.854
0.899


rs17133676
OGDH
0.002
0.849
0.820


rs2023945
CCDC46
0.002
0.765
0.742


rs1531817
PCSK6
0.002
0.785
0.141


rs1573994
ITPR2
0.002
0.845
0.285


rs3790515
RORC
0.002
0.775
0.495


rs3859534
LILRA6
0.002
0.737
0.441


rs11259333
FAM107B
0.002
0.693
0.144


rs11967633
TMEM63B
0.002
0.710
0.014


rs2071587
FOXN1
0.002
0.730
0.742


rs13225749
PTPRZ1
0.002
0.845
0.502


rs306410
ATP8A2
0.002
0.931
0.463


rs4775310
RORA
0.002
0.736
0.014


rs320109
RCOR2
0.002
0.811
0.295


rs155104
ITGA4
0.003
0.921
0.891


rs11208660
LEPR
0.003
0.895
0.295


rs625014
RAB31
0.003
0.818
0.164


rs10071707
PDZD2
0.003
0.919
0.587


rs222857
CLDN7
0.003
0.807
0.234


rs12582168
NCOR2
0.003
0.817
0.051


rs112544
LZTR1
0.003
0.870
0.128


rs1415701
L3MBTL3
0.003
0.862
0.724


rs995435
TGFBR2
0.003
0.843
0.393


rs7770046
TMEM181
0.003
0.781
0.185


rs3751909
FOXK2
0.003
0.731
0.352


rs17128050
GCH1
0.003
0.899
0.463


rs10423215
ZNF347
0.003
0.925
0.290


rs2186716
ST3GAL4
0.003
0.760
0.574


rs10989419
RP11-
0.003
0.859
0.058



35N6.1


rs7781464
CNTNAP2
0.003
0.876
0.135


rs2238202
RGS6
0.003
0.925
0.295
















SUPPLEMENTARY TABLE 8







Gene-SNP selection Top100 list, (BMC6-BMC0)-(AHC6-AHC0)












Nearest
ANOVA p-




SNP
Gene
value
GenTrainScore
ChiTest100














rs7210402
SGSM2
<0.001
0.839
0.863


rs1806516
P2RY6
<0.001
0.694
0.914


rs2345122
ZKSCAN2
<0.001
0.824
0.285


rs7004524
CSMD1
<0.001
0.849
0.018


rs17817463
DISC1
<0.001
0.733
0.421


rs11623922
KCNK13
<0.001
0.751
0.064


rs370133
NRCAM
<0.001
0.880
0.511


rs341397
RORA
<0.001
0.765
0.742


rs2427638
PCMTD2
<0.001
0.824
0.064


rs7224186
ARSG
<0.001
0.811
0.657


rs11672111
RDH13
<0.001
0.918
0.424


rs10889550
LEPR
<0.001
0.817
0.502


rs7203078
CMIP
<0.001
0.753
0.574


rs12451892
SGSM2
<0.001
0.826
0.141


rs7203568
WWOX
<0.001
0.815
0.778


rs4511641
RTN2
0.001
0.799
0.339


rs13379803
AKAP13
0.001
0.912
0.295


rs10888977
PPAP2B
0.001
0.837
0.399


rs2343869
SSPN
0.001
0.845
0.318


rs845204
CAMTA1
0.001
0.930
0.063


rs11079323
MSI2
0.001
0.928
0.009


rs3738919
ITGAV
0.001
0.925
0.595


rs12460755
INSR
0.001
0.927
0.433


rs7235783
SPIRE1
0.001
0.934
0.506


rs10071707
PDZD2
0.001
0.919
0.587


rs1018788
LARGE
0.001
0.895
0.474


rs4335165
MTUS1
0.001
0.753
0.287


rs389883
STK19
0.001
0.902
0.522


rs4801163
ZNF667
0.001
0.936
0.177


rs9304776
ZNF667
0.001
0.852
0.177


rs13225749
PTPRZ1
0.001
0.845
0.502


rs4384073
DDX58
0.001
0.778
0.203


rs2836416
ERG
0.001
0.830
0.857


rs9346818
LPAL2
0.001
0.891
0.522


rs3804267
PPAP2A
0.001
0.918
0.830


rs12246732
FAM107B
0.001
0.869
0.225


rs6785790
SETD2
0.001
0.854
0.048


rs16869706
SLIT2
0.001
0.897
0.655


rs10989419
RP11-
0.001
0.859
0.058



35N6.1


rs9853081
FOXP1
0.001
0.914
0.001


rs7712431
CSNK1A1
0.001
0.932
0.655


rs6415084
LPA
0.002
0.838
0.055


rs7076232
BTBD16
0.002
0.805
0.587


rs11814901
BTBD16
0.002
0.835
0.587


rs2481665
INADL
0.002
0.815
0.003


rs7625067
SETD2
0.002
0.813
0.009


rs2071587
FOXN1
0.002
0.730
0.742


rs10426628
SULT2B1
0.002
0.677
0.871


rs3893677
KCTD1
0.002
0.809
0.891


rs2010010
GALNT10
0.002
0.777
0.090


rs2176771
MMP16
0.002
0.675
0.080


rs12034925
DNAH14
0.002
0.838
0.433


rs17170270
TPK1
0.002
0.913
0.495


rs9390569
SASH1
0.002
0.930
0.506


rs11208660
LEPR
0.002
0.895
0.295


rs164577
SLC30A5
0.002
0.840
0.001


rs169250
FLJ25076
0.002
0.792
0.441


rs2260000
BAT2
0.002
0.810
0.526


rs2736172
BAT2
0.002
0.728
0.526


rs10814381
RNF38
0.002
0.841
0.354


rs1133195
MXI1
0.002
0.905
0.291


rs2298229
OLFM4
0.002
0.909
0.399


rs10979586
IKBKAP
0.002
0.935
0.260


rs1883414
HLA-DPB2
0.002
0.929
0.063


rs2371438
ERBB4
0.002
0.893
0.502


rs2010576
MICAL2
0.002
0.819
0.549


rs550338
SOX5
0.002
0.879
0.043


rs788332
MYH14
0.002
0.789
0.138


rs9726956
FGGY
0.002
0.856
0.029


rs8087174
OSBPL1A
0.002
0.869
0.639


rs151290
KCNQ1
0.002
0.762
0.463


rs3094476
KCTD5
0.002
0.850
0.001


rs876687
TGFBR2
0.002
0.847
0.502


rs3773661
TGFBR2
0.002
0.794
0.495


rs6775216
SHOX2
0.003
0.856
0.023


rs7901290
CAMK1D
0.003
0.900
0.672


rs3809572
SMAD3
0.003
0.726
0.495


rs2186716
ST3GAL4
0.003
0.760
0.574


rs11967633
TMEM63B
0.003
0.710
0.014


rs6925303
FYN
0.003
0.882
0.019


rs6914091
FYN
0.003
0.713
0.019


rs6930230
FYN
0.003
0.933
0.019


rs555225
ANK1
0.003
0.714
0.742


rs16890723
ANK1
0.003
0.704
0.820


rs11853311
SLCO3A1
0.003
0.799
0.440


rs6650615
MPPE1
0.003
0.916
0.290


rs1133195
MXI1
0.003
0.905
0.291


rs2286294
GLI3
0.003
0.959
0.137


rs17799872
ADCY3
0.003
0.746
0.421


rs2744805
RIMS3
0.003
0.785
0.614


rs3016562
PARK2
0.003
0.852
0.009


rs6868292
PPAP2A
0.003
0.876
0.290


rs16924332
ABCC9
0.003
0.937
0.778


rs2201945
PCDH7
0.003
0.844
0.295


rs10010739
PCDH7
0.003
0.899
0.030


rs2285431
HDAC9
0.003
0.837
0.360


rs10503284
CSMD1
0.003
0.719
0.143


rs3774491
CACNA1D
0.003
0.839
0.888


rs2518523
OR6K6
0.003
0.765
<0.001


rs16841047
OR6K6
0.003
0.937
<0.001








Claims
  • 1. A method of screening individuals at risk of developing insulin resistance comprising analyzing chromosomal DNA taken from the individual for the presence of at least one single nucleotide polymorphism (SNP) selected from the group consisting of
  • 2. A method of screening individuals at risk of developing type II diabetes (T2D) comprising analyzing chromosomal DNA taken from the individual for the presence of at least one single nucleotide polymorphism (SNP) selected from the group consisting of
  • 3. A method of identifying single nucleotide polymorphisms (SNPs) associated with insulin resistance comprising identifying SNPs linked with vesicle-associated membrane protein-associated protein A (VAPA) or protein inhibitor of activated STAT-1 (PIAS1) that are present in individuals having insulin resistant cells at statistically significant levels compared to individuals without insulin resistant cells.
  • 4. A method of screening individuals at risk of developing insulin resistance comprising analyzing chromosomal DNA taken from the individual for the presence of a single nucleotide polymorphism (SNP) rs2291726: TCTAGGGACACTTGAATCTTTTAATA[C/T]CTGAACCCCAAAAGCAGAGGGTACC, (SEQ ID NO: 9) Chr17:47039254, C→T, wherein an individual heterozygous or homozygous for the SNP is identified as having an increased risk of developing insulin resistance.
  • 5. A method of screening individuals at risk of developing type II diabetes (T2D) comprising analyzing chromosomal DNA taken from the individual for the presence of a single nucleotide polymorphism (SNP) rs2291726: TCTAGGGACACTTGAATCTTTTAATA[C/T]CTGAACCCCAAAAGCAGAGGGTACC, (SEQ ID NO: 9) Chr17:47039254, C→T, wherein an individual heterozygous or homozygous for the SNP is identified as having an increased risk of developing T2D.
  • 6. A method of identifying single nucleotide polymorphisms (SNPs) associated with insulin resistance comprising: providing a test population of healthy individuals with a body mass index of between 24.5 and 27.5 that undergo two interventions, wherein the first intervention is feeding on a high-carbohydrate diet and the second intervention is feeding on a moderate-carbohydrate diet for two test periods separated with ordinary eating habits;collecting fasting blood samples from individuals before and after each test period;analyzing the fasting blood samples for leukocyte gene expression levels and insulin resistance, wherein plasma protein levels are analyzed for visfatin, resistin, insulin, C-peptide, glucagon, plasminogen activator inhibitor-1, glucagon-like peptide-1, tumor necrosis factor alpha, interleukin-6, ghrelin, leptin, and gastric inhibitory polypeptide (GIP);performing pairwise comparisons (a) between results of the analysis of the individuals of the first intervention after and before the test period; (b) between results of the analysis of the individuals of the second intervention after and before the test period; (c) between results of the analysis of the individuals of the first intervention after the test period and results of the analysis of the individuals of the second intervention after the test period; and (d) between (a) and (b); andidentifying differentially expressed genes in response to each diet intervention period;genotyping all individuals in loci linked to the differentially expressed genes; andperforming a statistical analysis to determine SNPs significantly correlated with insulin resistance in individuals of the test population.
  • 7. A method for screening for candidate genes for molecular mechanisms involved in insulin resistance comprising the use of VAPA and plasma protein inhibitor of activated STAT-1 (PIAS 1).
  • 8. A method for diagnosing insulin resistance correlated a dietary disease comprising testing an individual's genomic DNA for the presence of at least one single nucleotide polymorphism (SNP) selected from the group consisting of
  • 9. The method according to claim 8, wherein the dietary disease is associated with glycemic load.
  • 10. A method of developing drugs for regulating an individual's glycemic response comprising using a marker selected from the group consisting of vesicle-associated membrane protein-associated protein A (VAPA), plasma protein inhibitor of activated STAT-1 (PIAS1),
  • 11. A method for providing a dietary plan for an individual genetically predisposed to type II diabetes (T2D) comprising, performing genomic typing of the individual's genomic DNA, wherein the typing comprises testing the individual's genomic DNA for the presence of at least one single nucleotide polymorphism (SNP) selected from the group consisting of
  • 12. A method for analyzing an individual's physiological response to dietary glycemic load comprising, performing genomic typing of the individual's genomic DNA, wherein the typing comprises testing the individual's genomic DNA for the presence of at least one single nucleotide polymorphism (SNP) selected from the group consisting of
  • 13. Use of vesicle-associated membrane protein-associated protein A (VAPA) and plasma protein inhibitor of activated STAT-1 (PIAS1) as candidate genes for molecular mechanisms involved in insulin resistance.
  • 14. Use of the genetic identified genetic SNP markers according to this invention in the diagnosis of insulin resistance correlated with dietary diseases, especially glycemic loads.
  • 15. Use of such markers according to claim 13 developing suitable drugs for regulating glycemic response in people with such diseases.
  • 16. Use of such markers according to claim 13 to explain individual physiological responses to dietary glycemic load characterized by such single nucleotide polymorphism (SNP) typing to provide concrete dietary advice to persons genetically predisposed to type II diabetes (T2D).
  • 17. Use of such markers according to claim 14 developing suitable drugs for regulating glycemic response in people with such diseases.
  • 18. Use of such markers according to claim 14 to explain individual physiological responses to dietary glycemic load characterized by such single nucleotide polymorphism (SNP) typing to provide concrete dietary advice to persons genetically predisposed to type II diabetes (T2D).
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/IB11/03038 12/13/2011 WO 00 10/16/2013
Provisional Applications (1)
Number Date Country
61424005 Dec 2010 US